# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION

**Washington, D.C. 20549**

# FORM 8-K

**Current Report**
**Pursuant to Section 13 or 15(d) of**
**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 22, 2016**

# ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

| **England and Wales** | **1-37368** | **Not Applicable** |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**101 Park Drive, Milton Park**
**Abingdon, Oxfordshire OX14 4RY**
**United Kingdom**
(Address of principal executive offices, including zip code)

**(44) 1235 430000**
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

As previously announced, Adaptimmune Therapeutics plc (the "Company") will give a live audio webcast today, April 22, 2016, in conjunction with its Investor and Analyst Day 2016. The webcast will include a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 7.01.

The live audio webcast and the accompanying slide presentation will be available through the investor section of the Company's website at http://ir.adaptimmune.com. The information contained on the Company's website is not part of this Form 8-K and is not incorporated by reference into this Form 8-K.

**Item 8.01 Other Events.**

On April 22, 2016, the Company issued a press release announcing the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB). The SAB will serve as a strategic resource for the Company and help to steer the Company's development efforts in the field of immuno-oncology. The press release is attached as Exhibit 99.2 hereto and is incorporated by reference herein.

On April 22, 2016, the Company issued a press release announcing that the Company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity Receptor T-cells) to describe its proprietary technology. The press release is attached as Exhibit 99.3 hereto and is incorporated by reference herein.

The information contained in Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following exhibits are furnished as part of this Report on Form 8-K:

| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Slide presentation to be presented at the Adaptimmune Investor and Analyst Day 2016 on April 22, 2016 (furnished pursuant to Item 7.01). |
| 99.2 | Press Release regarding SAB dated April 22, 2016. |
| 99.3 | Press Release regarding SPEAR T-cells™ dated April 22, 2016. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPTIMMUNE THERAPEUTICS PLC

Date: April 22, 2016

By: /s/ Margaret Henry
Name: Margaret Henry
Title: Corporate Secretary



**Exhibit Index**

| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Slide presentation to be presented at the Adaptimmune Investor and Analyst Day 2016 on April 22, 2016 (furnished pursuant to Item 7.01). |
| 99.2 | Press Release regarding SAB dated April 22, 2016. |
| 99.3 | Press Release regarding SPEAR T-cells™ dated April 22, 2016. |

Exhibit 99.1

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

APRIL 22, 2016

Adaptimmune

TRANSFORMING T CELL THERAPY



# DISCLAIMER

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may", "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

APRIL 22, 2016

James Noble
Chief Executive Officer

Adaptimmune

TRANSFORMING T CELL THERAPY



## TODAY'S AGENDA

The Role of T Cells in the Immuno-Oncology Landscape
*Helen Tayton-Martin, PhD, MBA; Chief Operating Officer, Adaptimmune*

SPEAR T Cells™: Adaptimmune's Proprietary Technology Platform
*Bent Jakobsen, PhD; Scientific Founder, Adaptimmune*

Adoptive T Cell Therapy: Clinical Activity of NY-ESO-1 in a Solid Tumor
*Stephan Grupp, MD, PhD; U.Penn Perelman School of Medicine*

NY-ESO-1 T Cell therapy in Multiple Myeloma: Long Term Efficacy and Persistence
*Aaron Rapoport, MD; U.Md Marlene & Stuart Greenebaum School of Medicine*

Update on Progress with NY-ESO TCR Accelerating Adaptimmune's Wholly-Owned Clinical Pipeline
*Rafael Amado, MD; Chief Medical Officer, Adaptimmune*

The Adaptimmune Pipeline Engine Manufacturing Excellence and Commercial Delivery
*Gwen Binder-Scholl, PhD; Chief Technology Officer, Adaptimmune*

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

- Proprietary SPEAR T cell technology uniquely delivers:
  - Correctly identified targets
  - Specificity and optimal affinity
  - "Supra-natural" TCRs to accelerate programs
  - Enhanced effectiveness of TCRs
    - Generation 2 and 3 TCRs
- No other company can currently deliver all of these
- New data on the above are being presented today

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

**Most compelling clinical data in the field**

- Multiple clinical responses in synovial sarcoma, a solid tumor
  - Large solid lesions resolved
  - Breakthrough status
  - Pivotal trial planned for around year end 2016
- Over 90% response rate in multiple myeloma study in conjunction with ASCT
- No other company is as far advanced as Adaptimmune in the clinic with a TCR T cell
- New updates presented on both diseases today

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

Clear scientific leadership in the field of T cell engineering

Most compelling clinical data in the field

Deep pipeline across major cancers

- Company INDs open for NY-ESO, MAGE-A10 and AFP
- Next company INDs due 2017
- These TCRs all derive from Adaptimmune's proprietary technology
- No other company has routinely delivered INDs from an in-house TCR platform
- Today, we will disclose:
  - Our next IND target
  - The pipeline coverage of tumors

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Strong financial position

- Current capital can fund the business through mid-2018

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Strong financial position
- Proven ability to execute

- Three INDs open
- Manufacturing processes optimized
- Goal: first TCR T cell therapy to market

Adaptimmune
TRANSFORMING T CELL THERAPY

# BUILDING A LEADER

## A HISTORY OF SCIENTIFIC PRE-EMINENCE

Origins of TCR technology

2005-2007 Collaboration with Steve Rosenberg, MD, Ph.D.

2008-2011 Collaboration with U. Penn

2016 + Adaptimmune SAB




Adaptimmune leadership position in:

- *Identifying targets*
- *Generating soluble TCRs used in R&D*
- *Engineering affinity optimized TCRs*
- *Cell Manufacturing*
- *TCR intellectual property*

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

## THE ROLE OF T CELLS IN THE IMMUNO-ONCOLOGY LANDSCAPE
APRIL 22, 2016

Helen Tayton-Martin, PhD, MBA
Chief Operating Officer

Adaptimmune
TRANSFORMING T CELL THERAPY



## WHY IMMUNOTHERAPY?

THE KEY TO TACKLING CANCER EFFECTIVELY IS IMMUNE ENGAGEMENT

- Cancers
  - Primarily derived from changes to self-proteins
  - Contain many mutations
  - Are heterogeneous, even in the same patient
  - Are good at mutating to avoid selective pressure
  - Deploy a range of tactics to avoid immune system detection

**Re-establishing T cell recognition and catalysing a polyclonal T cell response is key**

Adaptimmune
TRANSFORMING T CELL THERAPY

# IMMUNOTHERAPY – EMERGING EVIDENCE

## EARLY BEGINNINGS WITH TUMOR INFILTRATING LYMPHOCYTES

TIL Therapy

Adaptimmune
TRANSFORMING T CELL THERAPY

# IMMUNOTHERAPY – EMERGING EVIDENCE

## EARLY BEGINNINGS WITH TUMOR INFILTRATING LYMPHOCYTES

**TIL Therapy**

- TIL therapy can mediate significant tumor regression in patients heavily pre-treated with IL-2 in refractory metastatic melanoma
- Significant toxicities

VOLUME 23 · NUMBER 10 · APRIL 1 2005

JOURNAL OF CLINICAL ONCOLOGY

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

*Mark E. Dudley, John R. Wunderlich, James C. Yang, Richard M. Sherry, Suzanne L. Topalian, Nicholas P. Restifo, Richard E. Royal, Udai Kammula, Don E. White, Sharon A. Mavroukakis, Linda J. Rogers, Gerald J. Gracia, Stephanie A. Jones, David P. Mangiameli, Michelle M. Pelletier, Juan Gea-Banacloche, Michael R. Robinson, David M. Berman, Armando C. Filie, Andrea Abati, and Steven A. Rosenberg*

2005




Adaptimmune
TRANSFORMING T CELL THERAPY

## IMMUNOTHERAPY – EMERGING EVIDENCE

### IMMUNE-MODULATION – CHECKPOINT BLOCKADE – ANTI-CTLA-4




Adaptimmune
TRANSFORMING T CELL THERAPY

# IMMUNOTHERAPY – EMERGING EVIDENCE

## IMMUNE-MODULATION – CHECKPOINT BLOCKADE – ANTI-CTLA-4

TIL Therapy

↓

Anti-CTLA-4

- Anti-CTLA-4 antibodies block CTLA4 on T cells which disables their 'brakes'




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Postow, Callahan and Wolchok, J Clin Oncol 2015 33, 1974-1982

# IMMUNOTHERAPY – EMERGING EVIDENCE

## IMMUNE-MODULATION – CHECKPOINT BLOCKADE – ANTI-CTLA-4

TIL Therapy

↓

Anti-CTLA-4

- Ipilimumab can cure patients, response rate is low but significant (1/5 get long term survival)
- Immune-mediated toxicity and adaptive resistance

2010

Published in final edited form as:
*N Engl J Med*. 2010 August 19; 363(8): 711–723. doi:10.1056/NEJMoa1003466.

**Improved Survival with Ipilimumab in Patients with Metastatic Melanoma**

**F. Stephen Hodi, M.D., Steven J. O'Day, M.D., David F. McDermott, M.D., Robert W. Weber, M.D., Jeffrey A. Sosman, M.D., John B. Haanen, M.D., Rene Gonzalez, M.D., Caroline Robert, M.D., Ph.D., Dirk Schadendorf, M.D., Jessica C. Hassel, M.D., Wallace Akerley, M.D., Alfons J.M. van den Eertwegh, M.D., Ph.D., Jose Lutzky, M.D., Paul Lorigan, M.D., Julia M. Vaubel, M.D., Gerald P. Linette, M.D., Ph.D., David Hogg, M.D., Christian H. Ottensmeier, M.D., Ph.D., Celeste Lebbé, M.D., Christian Peschel, M.D., Ian Quirt, M.D., Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D., Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D.**
The authors' affiliations and participating investigators are listed in the Appendix




Adaptimmune
TRANSFORMING T CELL THERAPY

# IMMUNOTHERAPY – EMERGING EVIDENCE

## ANTI-PD-1 – NEXT STEP CHECKPOINT BLOCKADE




Adaptimmune
TRANSFORMING T CELL THERAPY

## IMMUNOTHERAPY – EMERGING EVIDENCE

### ANTI-PD-1 – NEXT STEP CHECKPOINT BLOCKADE

TIL Therapy

↓

Anti-CTLA-4

↓

Anti-PD-1

- Anti-PD-1 and anti-PDL-1 antibodies stop T cells from becoming fatigued, especially in the tumor




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Postow, Callahan and Wolchok, J Clin Oncol 2015 33, 1974-1982

# IMMUNOTHERAPY – EMERGING EVIDENCE

## ANTI-PD-1 – NEXT STEP CHECKPOINT BLOCKADE

2015

TIL Therapy

↓

Anti-CTLA-4

↓

Anti-PD-1


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

- Clear effects on survival in multiple indications
- Durable responses, lower toxicity

**Keytruda (anti PD-1 - Melanoma)**




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: www.Keytruda.com

# IMMUNOTHERAPY – EMERGING EVIDENCE

## CHECKPOINT COMBINATIONS




Adaptimmune
TRANSFORMING T CELL THERAPY

# IMMUNOTHERAPY – EMERGING EVIDENCE

## CHECKPOINT COMBINATIONS

TIL Therapy

↓

Anti-CTLA-4

↓

Anti-PD-1

↓

Anti-CTLA-4 + Anti-PD-1

- Enhanced effects with multiple immune checkpoint blockade




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: www.Opdivo.com

## IMMUNOTHERAPY CHALLENGES

STRONG EVIDENCE FOR T CELLS BUT…




Check-point blockade/TIL therapy requires effective pre-existing anti-tumor immunity

The endogenous immune response to self antigens is low affinity

Mutational burden is correlated with effectiveness of immunotherapy

Tumors are selected to avoid immune detection – a high affinity response is required

Adaptimmune
TRANSFORMING T CELL THERAPY

## IMMUNOTHERAPY CHALLENGES

STRONG EVIDENCE FOR T CELLS BUT…




Adaptimmune
TRANSFORMING T CELL THERAPY

# THE OPPORTUNITY FOR ENGINEERED T CELL THERAPY

## A POWERFUL MODALITY




- Ability to engineer-in effective tumor antigen specificity to T cells
- Specific therapy: Engineered T cells migrate to antigen / tumor and provide localized responses
- Ability to engineer-in alterations to overcome the tumor microenvironment (next generation)

Adaptimmune
TRANSFORMING T CELL THERAPY

# THERE ARE TWO MAIN WAYS TO REDIRECT A T CELL

## SYNTHETIC RECEPTORS (CAR) AND T CELL RECEPTORS (TCR)




Adaptimmune
TRANSFORMING T CELL THERAPY

# CAR T CELLS – EVIDENCE IN HEMATOLOGICAL CANCERS

## NOT EASILY TRANSFERABLE TO SOLID TUMORS

- Anti-CD19 CAR-Ts have demonstrated evidence of high tumor shrinkage and remissions in B cell malignancies




Median overall survival 9.0 months
Median follow-up: 5.9 months (1-45+ months)

**Historical SOC median survival ~3 months (O'Brien, et al, 2008)**

### Efficacy of CD19 CAR-Ts in **hematological** cancers

| | NOVARTIS | KITE | JUNO | |
|---|---|---|---|---|
| CAR-T product | CTL019 | KTE-C19 | JCAR-015 | JCAR-014 |
| Pediatric ALL | 94% CR, 73% CRM | 70% CR, 60% CRM | 64% CR, 45% CRM | - |
| Adult ALL | 82% CR, 67% CRM | - | - | 100% CR, 100% CRM |
| DLBCL | - | 70% CR, 50% CRM | - | 82% CR, 64% CRM |

*CAR – Chimeric Antigen Receptor, ALL – Acute Lymphoblastic leukemia, DLBCL – Diffuse Large B-Cell Lymphoma, CR - Complete Response, CRM – Complete Molecular Remission

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Juno Therapeutics; CITI Car-T / TCR launch initiation report, 2016

# CAR T CELLS – EVIDENCE IN HEMATOLOGICAL CANCERS

## NOT EASILY TRANSFERABLE TO SOLID TUMORS

- Anti-CD19 CAR-Ts have demonstrated evidence of high tumor shrinkage and remissions in B cell malignancies




Median overall survival 9.0 months
Median follow-up: 5.9 months (1-45+ months)

**Historical SOC median survival ~3 months (O'Brien, et al, 2008)**

### Efficacy of CD19 CAR-Ts in **hematological** cancers

| | NOVARTIS | KITE | JUNO | |
|---|---|---|---|---|
| CAR-T product | CTL019 | KTE-C19 | JCAR-015 | JCAR-014 |
| Pediatric ALL | 94% CR, 73% CRM | 70% CR, 60% CRM | 64% CR, 45% CRM | - |
| Adult ALL | 82% CR, 67% CRM | - | - | 100% CR, 100% CRM |
| DLBCL | - | 70% CR, 50% CRM | - | 82% CR, 64% CRM |

Two issues: very few targets and little evidence of efficacy in solid tumors

Adaptimmune
TRANSFORMING T CELL THERAPY

*CAR – Chimeric Antigen Receptor, ALL – Acute Lymphoblastic leukemia, DLBCL – Diffuse Large B-Cell Lymphoma, CR - Complete Response, CRM – Complete Molecular Remission

## OPTIMIZED AFFINITY TCR T CELLS

### ADDRESS SOLID TUMORS AND INTRACELLULAR TARGETS

- Optimized affinity TCR T cells demonstrate efficacy in **solid tumors**



Adaptimmune
TRANSFORMING T CELL THERAPY

Sources: SITC, November 2015

## OPTIMIZED AFFINITY TCR T CELLS

### ADDRESS SOLID TUMORS AND INTRACELLULAR TARGETS

- Optimized affinity TCR T cells demonstrate efficacy in **solid tumors**



- Vast majority of cancer targets are intracellular and ONLY engaged by T cells via TCRs

Adaptimmune
TRANSFORMING T CELL THERAPY

## DEVELOPING EFFECTIVE AFFINITY OPTIMIZED TCR T CELLS

### HIGH BARRIERS TO ENTRY

- Specialized data and expertise required to identify the correct peptide targets
- Challenging to identify TCRs
- Essential to optimize the affinity of the TCR
- Specialized expertise and assays required for establishing TCR specificity
- Manufacturing expertise for both cell and vector required
- Clinical expertise for safe administration and effective study design for cell therapy required

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE SPEAR T CELL PLATFORM UNIQUELY OVERCOMES THESE HURDLES




Adaptimmune
TRANSFORMING T CELL THERAPY

ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

# SPEAR T CELLS: ADAPTIMMUNE'S PROPRIETARY TECHNOLOGY PLATFORM

APRIL 22, 2016

Bent Jakobsen, Ph.D.
Chief Scientific Officer and Co-founder, Immunocore
Scientific Founder, Adaptimmune Therapeutics plc
Fellow of The Academy of Medical Sciences

Adaptimmune

TRANSFORMING T CELL THERAPY



# ADOPTIVE T CELL - MOST POWERFUL UNIT IN IMMUNOTHERAPY

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor has two important aspects
   - **Affinity**
   - **Specificity**




Adaptimmune
TRANSFORMING T CELL THERAPY

# ADOPTIVE T CELL - MOST POWERFUL UNIT IN IMMUNOTHERAPY

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor must have two important aspects
   - **Affinity**
   - **Specificity**
3. The T cell needs to be **resistant to suppression**




Adaptimmune
TRANSFORMING T CELL THERAPY

# ADOPTIVE T CELL - MOST POWERFUL UNIT IN IMMUNOTHERAPY

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor must have two important aspects
   - **Affinity**
   - **Specificity**
3. The T cell needs to be **resistant to suppression**
4. The T cell (either alone or via other mechanisms) needs to **'break cancer immune tolerance'**




Adaptimmune
TRANSFORMING T CELL THERAPY


AFFINITY & SPECIFICITY

# ADOPTIVE T CELL - MOST POWERFUL UNIT IN IMMUNOTHERAPY

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor has two important aspects
   - **Affinity**
   - **Specificity**




Adaptimmune
TRANSFORMING T CELL THERAPY

## TCR AFFINITY - DETERMINED BY THYMIC SELECTION

- The entire peptidome (all peptides) is presented in the thymus
- T cells undergo **positive** and **negative** selection within the cortex and medulla of the thymus




Adaptimmune
TRANSFORMING T CELL THERAPY

## NATURAL T CELLS ARE ILL-EQUIPPED TO CLEAR CANCER

- Due to negative selection virtually all circulating T cells that have self peptide specificity will have low affinity TCRs
  - This mechanism guards the body against autoimmunity
- However all reasonably prevalent peptide antigens of cancer relevance are of self origin
  - Many of these peptide antigens are derived from proteins for which the encoding gene is silenced (or severely suppressed) in all (or almost all) adult tissues

Adaptimmune
TRANSFORMING T CELL THERAPY

# VIRAL TCRS HAVE HIGHER AFFINITY THAN NATURAL CANCER TCRS




▲ MAGE-A4 $K_D$ ~ 64 mM

▲ MAGE-A10 $K_D$ ~ 2 mM
- Not a natural TCR
- Identified from proprietary TCR display libraries

Adaptimmune
TRANSFORMING T CELL THERAPY

Aleksic, M. et al. (2012). Eur J Immunol 10.1002/eji.201242606

## AFFINITY OPTIMIZING CANCER TCRs IS PIVOTAL TO T CELL FUNCTION

- Some non-engineered TCRs will recognise antigen well
  - e.g. NY-ESO
  - Even so, engineering improves antigen recognition
- Some non-engineered TCRs fail to recognise antigen well
  - e.g. MAGE-A4
  - Engineering enables antigen recognition

**Affinity engineering is a critical step in TCR optimization**

Adaptimmune
TRANSFORMING T CELL THERAPY

# NY-ESO: NATURAL VERSUS ENGINEERED TCR FUNCTIONALITY




Even for NY-ESO affinity engineering improves T cell function

Adaptimmune
TRANSFORMING T CELL THERAPY

# NY-ESO: NATURAL VERSUS ENGINEERED TCR FUNCTIONALITY




Even for NY-ESO affinity engineering improves cancer killing

Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A4: EFFECT OF OPTIMIZING TCR AFFINITY




Adaptimmune
TRANSFORMING T CELL THERAPY

## AFFINITY OPTIMIZING CANCER TCRs IS PIVOTAL TO T CELL FUNCTION

- Some non-engineered TCRs will recognise antigen well
  - e.g. NY-ESO
  - Even so, cancer cell killing is dramatically improved by affinity optimization
- Some non-engineered TCRs fail to recognise antigen well
  - e.g. MAGE-A4
  - The optimal affinity is crucial for T cell function and the same across all cancer cell lines

**Affinity engineering is a critical step in TCR optimization**

Adaptimmune
TRANSFORMING T CELL THERAPY


SPECIFICITY & TOXICITY

## SPECIFICITY AND NON-SPECIFICITY

### ON TARGET




Target antigen on normal tissue

### OFF TARGET (SPECIFIC)




Closely related antigen on normal tissue

### OFF TARGET (NON-SPECIFIC)




Promiscuous recognition (unrelated to target)

### ALLOREACTIVITY




Alternate HLA restriction

Adaptimmune
TRANSFORMING T CELL THERAPY

## SPECIFICITY: TARGET EXPRESSION

ON TARGET




Target antigen on normal tissue

**normal tissue**

Optimized target selection process

1. Select targets expressed on cancer cell
   - Low expression (due to HLA downregulation) overcome by **high affinity TCRs**
2. No / extremely low expression in normal tissue*

*Expression tolerable in some normal tissues (e.g. prostate, breast, pancreas, immuno-privileged tissues)

Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A4 - EXPRESSION IN CANCER




Adaptimmune
TRANSFORMING T CELL THERAPY

MAGE-A4 expression from cancer genome atlas (TCGA)

# MAGE-A4 - EXPRESSION IN NORMAL TISSUE




**Expression is absent / low in most adult non-reproductive tissues**

Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A10 - EXPRESSION IN CANCER




Adaptimmune
TRANSFORMING T CELL THERAPY

MAGE-A10 expression from cancer genome atlas (TCGA)

# MAGE-A10 - EXPRESSION IN NORMAL TISSUE




**Expression is absent / low in most adult non-reproductive tissues**

Adaptimmune
TRANSFORMING T CELL THERAPY

RNAseq (Log scale) GTEx Portal

## SPECIFICITY AND NON-SPECIFICITY

OFF TARGET (SPECIFIC)




Closely related antigen on normal tissue

Potential for off-target specificity can be analyzed because the antigen is short and linear

- X-Scan
  1. Identify potential targets via genome search
  2. Test recognition by high affinity TCR

Adaptimmune
TRANSFORMING T CELL THERAPY

# X-SCAN: INDIVIDUAL PEPTIDE POSITION SPECIFICITY TESTING

Essential to determine which amino acids are critical

This is achieved by Single Amino Acid Substitution Mapping (X-scan)

| T | A | R | G | E | T | H | E | R | E |
|---|---|---|---|---|---|---|---|---|---|
| A | A | R | G | E | T | H | E | R | E |
| C | A | R | G | E | T | H | E | R | E |
| D | A | R | G | E | T | H | E | R | E |
| E | A | R | G | E | T | H | E | R | E |
| F | A | R | G | E | T | H | E | R | E |
| G | A | R | G | E | T | H | E | R | E |
| H | A | R | G | E | T | H | E | R | E |
| I | A | R | G | E | T | H | E | R | E |
| K | A | R | G | E | T | H | E | R | E |
| L | A | R | G | E | T | H | E | R | E |
| M | A | R | G | E | T | H | E | R | E |
| N | A | R | G | E | T | H | E | R | E |
| P | A | R | G | E | T | H | E | R | E |
| Q | A | R | G | E | T | H | E | R | E |
| R | A | R | G | E | T | H | E | R | E |
| S | A | R | G | E | T | H | E | R | E |
| V | A | R | G | E | T | H | E | R | E |
| W | A | R | G | E | T | H | E | R | E |
| Y | A | R | G | E | T | H | E | R | E |

| T | A | R | G | E | T | H | E | R | E |
|---|---|---|---|---|---|---|---|---|---|
| A | I | K | - | - | M | - | - | E | D |
| C | L | H | | | | | | K | G |
| D | V | | | | | | | N | K |
| E | S | | | | | | | Q | |
| F | | | | | | | | S | |
| G | | | | | | | | Y | |
| H | | | | | | | | | |
| I | | | | | | | | | |
| K | | | | | | | | | |
| L | | | | | | | | | |
| M | | | | | | | | | |
| N | | | | | | | | | |
| P | | | | | | | | | |
| Q | | | | | | | | | |
| R | | | | | | | | | |
| S | | | | | | | | | |
| V | | | | | | | | | |
| W | | | | | | | | | |
| Y | | | | | | | | | |

TCR 'tolerance' motif

Search Human Genome for all possible peptide matches and investigate these via:

- *TCR recognition*
- *Peptide presentation*

Adaptimmune

TRANSFORMING T CELL THERAPY

## MAGE-A10 - TCR GENERATION AND SELECTION

1. Three TCRs selected by specificity testing from an original pool of 21 parentals
2. Affinity enhancement leads to 15 variants plus 3 parents and 1 reverted heavy chain parental for testing
3. Cell based potency and specificity testing to select five candidates from 2 parents
4. Additional efficacy testing resulted in two comparable leads for X scan evaluation




Adaptimmune
TRANSFORMING T CELL THERAPY

** Point mutation in heavy chain (corrected at level 2)*

# MAGE-A10 TCR: 'X-SCAN' SPECIFICITY ANALYSIS

## TCR PEPTIDE RECOGNITION MAPPING USING COMBINATORIAL AMINO ACID SUBSTITUTIONS

| POSITION | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| **G** | **L** | **Y** | **D** | **G** | **M** | **E** | **H** | **L** |
| **X** | L | Y | D | G | M | E | H | L |
| G | **X** | Y | D | G | M | E | H | L |
| G | L | **X** | D | G | M | E | H | L |
| G | L | Y | **X** | G | M | E | H | L |
| G | L | Y | D | **X** | M | E | H | L |
| G | L | Y | D | G | **X** | E | H | L |
| G | L | Y | D | G | M | **X** | H | L |
| G | L | Y | D | G | M | E | **X** | L |
| G | L | Y | D | G | M | E | H | **X** |




Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A10 TCR: 'X-SCAN' SPECIFICITY ANALYSIS

## TCR PEPTIDE RECOGNITION MAPPING USING COMBINATORIAL AMINO ACID SUBSTITUTIONS




Tolerated residues at each position cutoff:
>10% of native MAGE-A10 peptide response

| G | T | Y | D | G | M | E | L | L |
|---|---|---|---|---|---|---|---|---|
| A | Q | F | C | A | P | Q | I | V |
| R | V | D | N | L | G | F | M | T |
| K | L | E | M | I | L | G | H | I |
| C | S | I | A | T | A | I | G | M |
| Q | A | K | Q | P | V | K | A | F |
| E | C | L | S | S | D | M | P | C |
| T | M | M | F | H | H | N | V | Q |
| P | I | V | H | C | I | P | C | A |
| W | G | A | K | E | K | T | F | S |
| M | N | T | P | F | N | V | S | W |
| L | F | W | G | M | S | S | T | D |
| H | Y | C | L | Q | C | R | Y | K |
| S | H | H | E | D | E | A | N | R |
| I | D | S | I | W | T | C | R | H |
| F | E | N | V | K | W | H | Q | N |
| D | P | P | W | R | F | L | D | E |
| N | K | Q | Y | N | R | W | K | G |
| Y | W | G | R | V | Y | Y | E | P |
| V | R | R | T | Y | Q | D | W | Y |

| |
|---|
| >50% |
| >30% |
| >20% |
| >15% |
| >10% |
| NR |

Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A10 TCR SELECTION-MOTIF SEARCH AGAINST PROTEOME







These 8 peptides were tested with c796 and no responses detected

TCR specificity is a key component

Adaptimmune
TRANSFORMING T CELL THERAPY

## SPECIFICITY AND NON-SPECIFICITY

OFF TARGET (NON-SPECIFIC)




Promiscuous recognition (unrelated to target)

- Potential for off-target non-specific reactions are tested by examining the ability of high-affinity TCRs to react to a panel of normal cell-lines

Adaptimmune
TRANSFORMING T CELL THERAPY

# MAGE-A10 TCR - SCREENING AGAINST NORMAL PRIMARY CELLS

- MAGE-A10$^{c796}$T was evaluated in IFN-γ ELISpot assays against 59 normal primary cells expressing HLA-A2
- No increase above background levels with transduced T cells




Adaptimmune
TRANSFORMING T CELL THERAPY

## SPECIFICITY AND NON-SPECIFICITY

- Potential for alloreactivity are tested by examining the ability of high-affinity TCRs to react to a panel of normal cell-lines with alternate HLA restrictions

ALLOREACTIVITY


Alternate HLA restriction

Adaptimmune
TRANSFORMING T CELL THERAPY

## MAGE A10 TCR: ALLOREACTIVITY ASSAY

- Panel of EBV-transformed B cells expressing a range of HLA types
  - 67 cell lines expressing a total of 131 different HLA alleles
- Responses observed in cells expressing HLA-B*1501 and HLA-B*4601




HLA-B*1501 and HLA-B*4601 become exclusion criteria for clinical trial

Adaptimmune
TRANSFORMING T CELL THERAPY


TCRs WITH SUPRA-NATURAL SPECIFICITY

# TCR FROM DISPLAY LIBRARY HAS SUPRA-NATURAL AFFINITY




▲ MAGE-A10 $K_D$ ~ 2 μM
- Not a natural TCR
- Identified from proprietary TCR display libraries

Adaptimmune
TRANSFORMING T CELL THERAPY

Aleksic, M. et al. (2012). Eur J Immunol 10.1002/eji.201242606

## NATURAL TCRs TYPICALLY CAN RECOGNIZE ONE MILLION DIFFERENT PEPTIDES

- Thymic selection narrows TCR specificity / cross-reactivity spectrum
- TCR has to recognize approximately 1,000,000 peptides to be positively selected




Adaptimmune
TRANSFORMING T CELL THERAPY

## TCRs SELECTED FROM PHAGE LIBRARIES CAN HAVE SUPRA-NATURAL SPECIFICITY

- Thymic selection narrows TCR specificity / cross-reactivity spectrum
- TCR has to recognize approximately 1,000,000 peptides to be positively selected




Adaptimmune
TRANSFORMING T CELL THERAPY


FINDING THE RIGHT TARGETS

# THE SPECTRUM OF POTENTIAL CANCER TARGETS FOR IMMUNOTHERAPY




Adaptimmune
TRANSFORMING T CELL THERAPY

see http://cancerimmunity.org/peptide/ for a list of tumor antigens reported in the literature

## PEPTIDE TARGET VALIDATION VIA MASS SPECTROMETRY

- Many identified target peptides fail to be presented *in vivo*
  - PSCA 14-22 (ALQPGTALL)
  - WT1 126-134 (RMFPNAPYL)
  - Telomerase 540-548 (ILAKFLHWL)
    - Not found by Adaptimmune mass spectrometry
    - Not detected by potent TCRs / T cells

- Adaptimmune **ONLY** considers peptides to be validated if detected by mass spectrometry
  - Currently ~ 660,000 unique peptides within our databases

Adaptimmune
TRANSFORMING T CELL THERAPY

# RECENTLY FILED PATENTS ON 63 TARGETS

## 873 PEPTIDES




Adaptimmune
TRANSFORMING T CELL THERAPY


GENERATION 2: MAKING T CELLS RESISTANT TO SUPPRESSION

# ADOPTIVE T CELL : GENERATION 2

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor must have two important aspects
   - **Affinity**
   - **Specificity**
3. The T cell needs to be **resistant to suppression**




Adaptimmune
TRANSFORMING T CELL THERAPY

## OVERCOMING INHIBITION IN THE TUMOUR MICROENVIRONMENT

### GEN2(A) MAKES T CELLS INSENSITIVE TO INHIBITORY FACTOR X




Adaptimmune
TRANSFORMING T CELL THERAPY

## OVERCOMING INHIBITION IN THE TUMOUR MICROENVIRONMENT

### GEN2(A) MAKES T CELLS INSENSITIVE TO INHIBITORY FACTOR X




Adaptimmune
TRANSFORMING T CELL THERAPY

## OVERCOMING INHIBITION IN THE TUMOUR MICROENVIRONMENT

### GEN2(A) MAKES T CELLS INSENSITIVE TO INHIBITORY FACTOR X

- Gen2(A) TCR maintains enhanced killing in the presence of inhibitors




Adaptimmune
TRANSFORMING T CELL THERAPY

## OVERCOMING INHIBITION IN THE TUMOUR MICROENVIRONMENT

### GEN2(C) MAKES T CELLS INSENSITIVE TO INHIBITORY FACTORS Y & Z




Adaptimmune
TRANSFORMING T CELL THERAPY

## OVERCOMING INHIBITION IN THE TUMOUR MICROENVIRONMENT (II)

### GEN2(C) MAKES T CELLS INSENSITIVE TO INHIBITORY FACTORS Y & Z

- Gen2(C) TCR maintains enhanced killing in the presence of inhibitors




Adaptimmune
TRANSFORMING T CELL THERAPY


GENERATION 3: ENABLING T CELLS TO HELP
'BREAK CANCER IMMUNE TOLERANCE

# ADOPTIVE T CELL : GENERATION 3

Four components to an effective adoptive therapy:

1. T cell must recognize a cancer cell via a **guiding receptor**
2. The guiding receptor must have two important aspects
   - **Affinity**
   - **Specificity**
3. The T cell needs to be **resistant to suppression**
4. The T cell (either alone or via other mechanisms) needs to **'break cancer immune tolerance'**




Adaptimmune
TRANSFORMING T CELL THERAPY

## BROADENING THE IMMUNE RESPONSE

### GEN3(B) ENHANCES CD40L EXPRESSION TO PROMOTE EPITOPE SPREADING

- Gen2(B) enhances TCR mediated CD40L upregulation on $CD4^+$ T cells in response to antigen positive targets




Adaptimmune
TRANSFORMING T CELL THERAPY

## GENERATION 2 AND GENERATION 3 T CELLS

- Several Generation 2 projects that help T cells overcome sensitivity to inhibitory factors in the tumor microenvironment
- Several Generation 3 projects that enable T cells to promote epitope spreading and therefore have the potential to aid the breaking of tumor immune tolerance
- First Generation 2 / 3 IND anticipated in 2017

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE T CELL TECHNOLOGY

### SUMMARY

- TCR affinity optimization crucial for best T cell response to cancer
- Specificity crucial for lowest toxicity – supra-naturally specific TCRs identified from proprietary display libraries
- Several Generation 2 technologies making T cells resistant to tumour microenvironment inhibitory factors
- Several Generation 3 technologies enabling T cells to facilitate breaking immune tolerance to tumor

Adaptimmune
TRANSFORMING T CELL THERAPY

ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

# ADOPTIVE T CELL THERAPY: CLINICAL ACTIVITY OF NY-ESO-1 IN A SOLID TUMOR

APRIL 22, 2016

Stephan Grupp, M.D., Ph. D.
Novotny Professor of Pediatrics
University of Pennsylvania
Perelman School of Medicine

Adaptimmune

TRANSFORMING T CELL THERAPY



# 93% CR RATE FOR RELAPSED/REFRACTORY ALL AFTER CTL019

- 59 r/r pediatric ALL pts: 55 in CR at one mo (93%) median f/u 12 mo
- Six went to subsequent transplant, one to DLI
- Six mo RFS: 76% (95%CI:0.65,0.89)
- 12 mo RFS: 55% (95%CI: 0.42,0.73)
- No relapses past one year
- 18 patients in remission beyond one year, 13 without further therapy




The Children's Hospital of Philadelphia® CANCER CENTER

Adaptimmune
TRANSFORMING T CELL THERAPY

## TWO APPROACHES TO GENETICALLY ENGINEERED T CELLS: CARs AND TCRs


- Sensitive signal amplification derived by evolution
- Hard to isolate and engineer
- Low avidity
- Can target intracellular proteome (3/4)
- Requires MHC-I expression and HLA matching on tumor

- Signal amplification from synthetic biology
- Easier to make
- Avidity controllable
- Targets only surface structures (1/4)
- MHC independent: "off the shelf"

**Toxicity difficult to predict…**

Adaptimmune
TRANSFORMING T CELL THERAPY

## NY-ESO-1

### A CANCER-TESTIS ANTIGEN HIGHLY EXPRESSED IN SYNOVIAL SARCOMA

- 76% of synovial sarcomas express strong staining, defined as 2-3+ in >50-70% *(Lai, Mod Pathol 2012)*
- A TCR recognizing NY-ESO-1 in the context of HLA:A0201 was cloned from a patient with cancer, then modified for higher affinity *(Zhao, J Immunol, 2007)*

NY-ESO IHC screening on Synovial Sarcomas



Adaptimmune
TRANSFORMING T CELL THERAPY

## TWO CLINICAL TRIALS OF ADAPTIMMUNE'S NY-ESO-1 TCR IN SYNOVIAL SARCOMA

- **Investigator Initiated Trial**: The Surgical Branch of the NCI did a study of Adaptimmune's NY-ESO-1-transduced lymphocytes in synovial sarcoma (Cy/Flu + HD IL-2)
  - Partial response in 4 of 6 synovial sarcomas *(Robbins et al, JCO 2011)*
  - Follow-up report: Objective responses in 11 of 18 synovial cell sarcomas (61%) *(Robbins, Clin Can Res 2015)*
  - Estimated 3-year OS: 38%; 5-yr OS 14%
- **Adaptimmune Trial**: Included changes to improve safety and treatment feasibility
  - Determine response rate without HD IL-2
  - Use of lentiviral vector
  - Central manufacturing site (GMP) and cryopreserved final product
  - Recent new cohort with cyclophosphamide alone (no fludarabine)
  - Recent additional cohort of NY-ESO-1 low expressors (<2+ in 50%)

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE'S NY-ESO-1 SARCOMA TRIAL SCHEMA




**T cell infusion:**
(Mean=5x10$^9$ cells*)

No IL-2




**Supportive care:**
Infection prophylaxis, observation for CRS, GvHD, f/u safety and efficacy

Adaptimmune
TRANSFORMING T CELL THERAPY

* 1 x 10$^9$/kg (min 1 x 10$^7$/kg; max 40x10$^9$ total)

## NY-ESO-1 SARCOMA STUDY: COHORT 1

### 60% OBJECTIVE RESPONSE RATE IN PATIENTS TREATED AT TARGET DOSE

| Patient | NY-ESO Staining (archival tissue) | Total Transduced T cells ($x10^9$) | NY-ESO TCR+ T cells / kg ($x10^6$) | Best Overall Response |
|---|---|---|---|---|
| 200 | 2-3+ in >50% | 14.4 | 91.3 | SD |
| 201 | 3+ in 100% | 8.3 | 165.01 | CR |
| 202* | 3+ in 30% | 6.6 | 69.99 | PR |
| 204 | 2-3+ in 50% | 3.8 | 60.32 | PR |
| 205 | 3+ in ~100% | 3.4 | 62.50 | PR |
| 261 | 3+ >99% | 0.72 | 9.11 | SD |
| 206 | 2+ >50% | 0.45 | 5.51 | SD |
| 207 | 3+ >80% | 2.67 | 25.36 | SD |
| 208 | 3+ >95% | 4.84 | 47.97 | PR |
| 209 | 3+ in ~100% | 2.51 | 27.9 | PR |
| 263 | 3+ >50% | 2.51 | 45.39 | PD |
| 230 | 2-3+ in 100% | 7.86 | 143 | PD |
| Mean | | 4.17 | 57.4 | |

Adaptimmune
TRANSFORMING T CELL THERAPY

*Treated in cohort 1 under a protocol exception

## SYNOVIAL SARCOMA OVERALL SURVIVAL COHORT 1




Source: Adaptimmune
April 2016 cutoff

- 5/12 patients alive 4/2016
  - 1 year survival: 75%
  - 2 year survival: 25%

Adaptimmune
TRANSFORMING T CELL THERAPY

## SYNOVIAL SARCOMA STUDY: ALL COHORTS INCIDENCE (N,%) OF SAEs (>1 OCCURRENCE)

| Preferred Term | Number of Subjects by Maximum Grade (N=16) | | |
|---|---|---|---|
| | All SAEs | Related* | Fatal |
| Pyrexia | 4 (25) | 2 (12.5) | 0 |
| Cytokine release syndrome | 2 (12.5) | 2 (12.5) | 0 |
| Lymphopenia/Lymphocyte count decreased | 2 (12.5) | 2 (12.5) | 0 |
| Neutropenia | 2 (12.5) | 2 (12.5) | 0 |
| Febrile neutropenia | 2 (12.5) | 1 (6.3) | 0 |
| Thrombocytopenia | 2 (12.5) | 2 (12.5) | 0 |
| Dyspnea | 2 (12.5) | 1 (6.3) | 0 |

January 2016 cutoff

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune

## PHASE I/II STUDY IN SYNOVIAL SARCOMA

### RADIOGRAPHIC PSEUDOPROGRESSION AND RESPONSE OF LUNG METASTASES LEADING TO COMPLETE RESPONSE

**Baseline:**
Bilateral miliary metastatic disease



**Day +2:**
Pseudoprogression due to immune infiltration




**Day +101:**
Complete Response



Adaptimmune
TRANSFORMING T CELL THERAPY

Source: AACR April 2015

## CLINICAL RESPONSE FOLLOWED BY RESECTION AT PROGRESSION



1/22/14 3/3/14 4/7/14

- Mass began to show regrowth ~6 months
- Surgically resected at 7 months
  - No NY-ESO-1 TCR cells found in tumor
  - Substantial CD4+ T cells

No evidence of disease 27 months post NY-ESO-1 T cell infusion; 20 months from surgical resection of metastasis

Adaptimmune
TRANSFORMING T CELL THERAPY

## NEAR COMPLETE RESPONSE TO NY-ESO-1 T CELLS OF UNRESECTABLE PRIMARY TUMOR IN THE KNEE




- Complete surgical resection accomplished, no irradiation
- Local disease remained controlled; patient developed lung metastasis with loss of NY-ESO-1

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: SITC, November 2015

# TUMOR SHRINKAGE OVER THE COURSE OF SEVERAL MONTHS FOLLOWING NY-ESO-1 TCR FOR SYNOVIAL SARCOMA

## MULTIPLY RECURRENT, UNRESECTABLE PULMONARY MASSES




Ongoing PR 400+ days post T cell infusion

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune

# T CELLS TRAFFIC TO THE SITE OF TUMOR

## AT RESECTION REMAINING TUMOR WAS NY-ESO NEGATIVE







Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune

# CLINICAL RESPONSES OBSERVED ACROSS A SPECTRUM OF NY-ESO-1 EXPRESSION

## RESPONSE IN A PATIENT WITH LOW NY-ESO-1 EXPRESSION



Baseline
11-05-13

Month 3
02-18-14



Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune

# CLINICAL RESPONSES OBSERVED ACROSS A SPECTRUM OF NY-ESO-1 EXPRESSION

## RESPONSE IN A PATIENT WITH VERY HIGH NY-ESO-1 EXPRESSION



Baseline

Month 6



Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune

# NY-ESO-1 SARCOMA STUDY

## DURABLE PERSISTENCE OF NY-ESO-T

Subjects receiving minimum evaluable dose
(>1x10$^9$ NY-ESO-1$^{c259}$T cells)




- Among evaluable subjects, higher peak persistence was observed among responders compared to non responders
- To date, among responders, NYESO-1 T cells have been detected up to 21 months.

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: November SITC, 2015

## NY-ESO-1 SARCOMA STUDY

### REMARKABLE PERSISTENCE OF NY-ESO TCR+ T CELLS IN SARCOMA PATIENT EXPERIENCING A COMPLETE RESPONSE




Adaptimmune
TRANSFORMING T CELL THERAPY

## CLINICAL SUMMARY

- NY-ESO-1 TCR T cells has manageable toxicity
  - Fever, low grade cytokine release common in the week following cell infusion
- Anti-tumor activity confirmed in the absence of HD IL-2:
  - 60% response without HD IL-2
- Pseudo-progression, gradual reductions in tumor burden and NY-ESO TCR+ T cells in resected tumor indicate immunologic basis for response
- NY-ESO-1 TCR T cells are highly persistent
  - Longest persistence observed with a TCR to date
- Mechanisms of resistance:
  - Elucidating mechanisms of immune escape through analysis of pre- and post-treatment tissue

Adaptimmune
TRANSFORMING T CELL THERAPY

ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

# NY-ESO-1 T CELL THERAPY IN MULTIPLE MYELOMA: LONG TERM EFFICACY AND PERSISTENCE

APRIL 22, 2016

Aaron P. Rapoport, MD
Professor of Medicine
Gary Jobson Professor in Medical Oncology
University of Maryland Marlene and Stewart Greenebaum Cancer Center

Adaptimmune

TRANSFORMING T CELL THERAPY



# MULTIPLE MYELOMA

## MODEL BLOOD CANCER









- The American Cancer Society estimates that in 2016*
  - ~30,330 new cases will be diagnosed
  - ~12,650 deaths will occur
  - 1/143 lifetime risk
- Slightly more common in men than women
- Incidence in African-Americans about twice that in Caucasians
- Mean age is approximately 60 years

Adaptimmune
TRANSFORMING T CELL THERAPY

*https://cancerstatisticscenter.cancer.org/?_ga=1.104040064.1641643651.1460834859#/cancer-site/Myeloma

## ADVANTAGES OF CELLULAR IMMUNOTHERAPY

- Kills “resistant” tumors (e.g. 17p – P53 del)
- Penetrates “sanctuary” sites (e.g. CNS)
- Through expansion and serial killing can eradicate “large” tumors
- Can generate long-lived “memory” responses to protect against recurrence
- High degree of specificity, avoids second malignancies and immunodepletion

Adaptimmune
TRANSFORMING T CELL THERAPY

## WHY TARGET CANCER TESTIS ANTIGENS IN MM

- Advanced MM frequently expresses the Cancer Testis antigens NY-ESO-1 or LAGE-1
  - Expression of Cancer Testis antigens is associated with poor prognosis in myeloma[1]
- Adaptimmune's NY-ESO-1 TCR was tested in multiple myeloma
  - Same epitope present on both antigens[2]

Adaptimmune
TRANSFORMING T CELL THERAPY

1. Dhodapkar et al, Cancer Immun, 2003
Atanackovic et al, Clin Cancer Res, 2009; and others
2. Li et al, Nat Bio, 2005; Robbins et al, JCO 2011 and CCR 2014

## PHASE I/II STUDY IN MULTIPLE MYELOMA




- All enrolled patients (n=25): Symptomatic myeloma with active disease
- High risk population
  - Average of 3 prior Rx; range 1-5
    - 7 patients had prior autologous stem cell transplant (ASCT)
  - Twelve with cytogenetic abnormalities (7 categorized as high-risk)
- Conditioned with high-dose melphalan followed 2 days later by ASCT

Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### STUDY PATIENT POPULATION

- Medically eligible for transplant
- High risk or relapsed disease
- ECOG performance status: Grade 0-2
- HLA-0201
- Myeloma cells express NY-ESO-1 and/or LAGE-1 by RT-PCR

### STUDY ENDPOINTS

- Safety and Tolerability
- Secondary:
  - Clinical Responses
  - Proof of Mechanism

### RESPONSE ASSESSMENTS

- International Uniform Response Criteria
  - Additional category of nCR: -ve M spike but +ve by immunofixation

Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### RESPONSE ASSESSMENT

| Best Response by day 100 | Number of Patients | % Total |
|---|---|---|
| CR | 3 | 14% |
| nCR | 10 | 45% |
| VGPR | 2 | 9% |
| PR | 5 | 23% |
| SD | 1 | 5% |
| PD | 1 | 5% |
| **Not assessable*** | **3** | **NA** |
| Total evaluable | 22 | 100% |

* Patients with VGPR or better going into transplant

- RR= 91%
- CR+nCR+VGPR = 68%

Adaptimmune
TRANSFORMING T CELL THERAPY

Rapoport et al. Nat Med 21(8):914-21

# PHASE I/II STUDY IN MULTIPLE MYELOMA

## DURATION OF RESPONSE




Cut-off date: March 2015

- Overall survival as of January 2016:
  - Median OS ~3 years (Cut-off date: January 2016)
- Progression free survival (PFS) as of November 2015
  - Median PFS = 19.1 months (Cut-off date: November 2015)

Adaptimmune
TRANSFORMING T CELL THERAPY

Rapoport et al. Nat Med 21(8):914-21

## MULTIPLE MYELOMA OVERALL SURVIVAL

MEDIAN SURVIVAL: ~3 YEARS (RANGE: 28 WEEKS TO 4.25+ YEARS)




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Adaptimmune
January 2016 Cutoff

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### NY-ESO-1 T CELLS TRAFFIC TO SITES OF TUMOR (BONE MARROW)




Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### RESOLUTION OF DISEASE IN BONE MARROW AND PLASMACYTOMA BY DAY 56 POST-THERAPY WITH NY-ESO-1 TCR TRANSDUCED T CELLS

Pre-treatment





Day 56






Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

MASSIVE INFILTRATION OF T CELLS INTO MARROW CORRELATE WITH RESPONSE FOLLOWING SECOND INFUSION




Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### ANTIGEN SPREADING: CLONAL EXPANSION OF TWO TCR CLONOTYPES

Patient 253




Day 28 post infusion

Day 68 post infusion




Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### INCIDENCE (N,%) OF ALL SAEs (>1 OCCURRENCE)

| Preferred Term | Number of Subjects by Maximum Grade (N=25)* | | |
|---|---|---|---|
| | All SAEs** | Related | Fatal |
| Neutropenia | 4 (16.0) | 2 (8.0) | 0 |
| Pyrexia | 3 (12.0) | 1 (4.0) | 0 |
| Atrial fibrillation | 3 (12.0) | 0 (0.0) | 0 |
| Graft versus host disease | 2 (8.0) | 2 (8.0) | 0 |
| Diarrhoea | 2 (8.0) | 2 (8.0) | 0 |
| Hypoxia | 2 (8.0) | 1 (4.0) | 0 |
| Staphylococcal infection | 2 (8.0) | 0 (0.0) | 0 |

*No episodes of CRS SAEs were reported

**Includes all events reported as of 27Jan2016 excluding disease progression and laboratory abnormalities with the investigations and nutritional disorders SOCs except for combined haematologic terms above

Adaptimmune
TRANSFORMING T CELL THERAPY

# PHASE I/II STUDY IN MULTIPLE MYELOMA

## NY-ESO-1 T CELL PERSISTENCE IN PERIPHERAL BLOOD




IN FURTHER FOLLOW UP, NY-ESO-1 T CELLS ARE DETECTED BEYOND THREE YEARS IN PERIPHERAL BLOOD

Adaptimmune
TRANSFORMING T CELL THERAPY

## PHASE I/II STUDY IN MULTIPLE MYELOMA

### CONTINUED EXPRESSION OF NY-ESO-1 TCR IN BLOOD AND AT SITE OF TUMOR: DAY 360




Adaptimmune
TRANSFORMING T CELL THERAPY

# PHASE I/II STUDY IN MULTIPLE MYELOMA

## PERSISTENCE AND RELAPSE CORRELATION

| Patient ID | Timepoint at relapse | Best response | Persistence of NY-ESO T at relapse | Antigen expression on tumor at relapse? |
|---|---|---|---|---|
| 250 | 1 year | sCR | Y | N |
| 200 | 1 year | nCR | Y | N |
| 252 | 2.75 year | PR | N | Y |
| 253 | 4 months | nCR | N | Y |
| 204 | 6 months | nCR | N | Y |
| 254 | 6 months | PR | Y | N |
| 255 | 1.75 years | nCR | N | Y |
| 209 | 8 months | nCR | N | Y |
| 257 | 4 months | nCR | N | Y |
| 258 | 9 months | nCR | N | Y |
| 259 | 9 months | sCR | N | Y |
| 261 | 3 months | PR | N | Y |
| 262 | 5 months | PR | N | Y |
| 263 | 9 months | PR | N | Y |

- At the time of relapse, blood and tumor were evaluated for NY-ESO-1 persistence and antigen, respectively
- Relapse corresponds to loss of persistence or loss of antigen

Adaptimmune
TRANSFORMING T CELL THERAPY

# PD-L1 EXPRESSION UPREGULATED IN MYELOMA CELLS AT PROGRESSION

## PLANNED COMBINATION STUDY NY-ESO-1 T CELLS + PD-1 INHIBITOR




### Planned Study

- Patients with Relapsed/refractory myeloma
- Cyclophosphamide/Fludarabine conditioning

Randomization 1:1

→ NY-ESO-1

→ NY-ESO-1 + anti-PD1

Adaptimmune
TRANSFORMING T CELL THERAPY

## SUMMARY

- Infusion of autologous T cells engineered with Adaptimmune's affinity enhanced TCR specific for NY-ESO-1 and LAGE-1 antigens is well tolerated
- The duration of response is better than would be expected with transplant alone
- Toxicity related to cytokine release syndrome has not been observed
- Prolonged persistence (without IL-2) and trafficking of cells to bone marrow were detected
- Initial data suggest infused cells remain functional, without exhaustion, and include a diversity of phenotypes
- Upregulation of PDL-1 in relapsed patients supports combination studies

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

## UPDATE ON PROGRESS WITH NY-ESO TCR
APRIL 22, 2016

Rafael Amado, M.D.
Chief Medical Officer

Adaptimmune
TRANSFORMING T CELL THERAPY



# INDUSTRY-LEADING TCR PIPELINE IN SOLID AND HEMATOLOGIC CANCERS

## ONGOING PROGRAMS FOR NY-ESO

| INDICATION | RESEARCH / PRE-IND / PHASE I/II | STATUS |
|---|---|---|
| Synovial Sarcoma | Cohort 1: High NY-ESO expression, 12 patients | Complete |
| | Cohort 2: Low NY-ESO expression, 10 patients | Enrolling |
| | Cohort 3: Removal of fludarabine, 10 patients | Enrolling |
| | Cohort 4*: Modified CTX / fludarabine, 10 patients | Opening 2016 |
| Multiple Myeloma | Autologous SCT, 25 patients (Rapoport Nat Med, 2015) | Complete |
| | Combination study, no auto SCT; 2 cohorts | In planning |
| Ovarian | 10 patients | Enrolling |
| Melanoma | 6 patients | Enrolling; potential for combination study |
| Non-small cell lung cancer | 10 patients, Stage IIIb / IV NSCLC | Initiated Q4 2015 |
| Investigator Initiated studies | NCI: synovial sarcoma (16 patients) and melanoma (13 patients) | Complete |
| | ATTACK: Esophageal: 12 patients | Active; recruitment to resume |

*Pending analysis of cohort 3

Adaptimmune
TRANSFORMING T CELL THERAPY

# INDUSTRY-LEADING TCR PIPELINE IN SOLID AND HEMATOLOGIC CANCERS

## ONGOING PROGRAMS FOR NY-ESO

| INDICATION | RESEARCH | PRE-IND | PHASE I/II | STATUS |
|---|---|---|---|---|
| Synovial Sarcoma | Cohort 1: High NY-ESO expression, 12 patients | | | Complete |
| | Cohort 2: Low NY-ESO expression, 10 patients | | | Enrolling |
| | Cohort 3: Removal of fludarabine, 10 patients | | | Enrolling |
| | Cohort 4*: Modified CTX / fludarabine, 10 patients | | | Opening 2016 |
| Multiple Myeloma | Autologous SCT, 25 patients (Rapoport Nat Med, 2015) | | | Complete |
| | Combination study, no auto SCT; 2 cohorts | | | In planning |
| Ovarian | 10 patients | | | Enrolling |
| Melanoma | 6 patients | | | Enrolling; potential for combination study |
| Non-small cell lung cancer | 10 patients, Stage IIIb / IV NSCLC | | | Initiated Q4 2015 |
| Investigator Initiated studies | NCI: synovial sarcoma (16 patients) and melanoma (13 patients) | | | Complete |
| | ATTACK: Esophageal: 12 patients | | | Active; recruitment to resume |

*Pending analysis of cohort 3

Adaptimmune
TRANSFORMING T CELL THERAPY

# SARCOMAS

## A DIVERSE COLLECTION OF UNCOMMON MESENCHYMAL TUMORS




Adaptimmune
TRANSFORMING T CELL THERAPY

Ducimetiere et al. PLoS ONE 6(8): e20294.
doi:10.1371/journal.pone.0020294. epub AUG 2011

## SARCOMA DEMOGRAPHICS AND MORTALITY

### RELAPSED METASTATIC SOFT TISSUE SARCOMA REPRESENTS AN UNMET MEDICAL NEED

| Disease | Incidence US/EU | Annual Mortality US/EU |
|---|---|---|
| Synovial Sarcoma & Myxoid Round Cell Liposarcoma | 2,400-3,000 | 840-1,050 |

**Breakthrough Designation:** Granted in the U.S. on February 4, 2016

*"for the treatment of HLA-A*0201, HLA-A*0205, HLA-A*0206 allele-positive patients with inoperable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the NY-ESO-1 tumor antigen"*

**Orphan Designation:** Granted in the U.S. on March 29, 2016

*"autologous CD4+/CD8+ NY-ESO-$1^{c259}$-T cells for the treatment of soft tissue sarcoma"*

Adaptimmune
TRANSFORMING T CELL THERAPY

## MYXOID ROUND CELL LIPOSARCOMA

### NEXT SOFT TISSUE SARCOMA TO BE STUDIED WITH ADAPTIMMUNE'S NY-ESO-1 TCR

- Represent 30-35% of all liposarcomas; 10% of all soft tissue sarcomas
- 80-90% express NY-ESO at high levels
- Characterized by chromosomal translocation (t(12;16)(q13;p11); as in the case of synovial sarcomas, it allows for accurate diagnosis)
- Present primarily in the extremities, particularly the thigh, and in the trunk and retroperitoneum
- Localized disease is managed with surgery, radiation and chemotherapy
- One third of patients develop metastatic disease with multifocal spread, commonly to the bone and lungs.
- Chemotherapy has a limited, non-curative role in metastatic disease

Adaptimmune
TRANSFORMING T CELL THERAPY

WHO Classification: https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb5/bb5-classifsofttissue.pdf

## MYXOID ROUND CELL LIPOSARCOMA

### NY-ESO IS HIGHLY EXPRESSED IN THE MAJORITY OF MRCLS




Adaptimmune
TRANSFORMING T CELL THERAPY

Hemminger J, Modern Pathology 26, 2013

# NY-ESO CLINICAL PROGRAM UPDATE

## REGISTRATION IN SOFT TISSUE SARCOMA


*Pending analysis of cohort 3

Adaptimmune
TRANSFORMING T CELL THERAPY

# INDUSTRY-LEADING TCR PIPELINE IN SOLID AND HEMATOLOGIC CANCERS

## ONGOING PROGRAMS FOR NY-ESO

| INDICATION | RESEARCH / PRE-IND / PHASE I/II | STATUS |
|---|---|---|
| Synovial Sarcoma | Cohort 1: High NY-ESO expression, 12 patients | Complete |
| | Cohort 2: Low NY-ESO expression, 10 patients | Enrolling |
| | Cohort 3: Removal of fludarabine, 10 patients | Enrolling |
| | *Cohort 4: Modified CTX / fludarabine, 10 patients | Opening 2016 |
| Multiple Myeloma | Autologous SCT, 25 patients. (Rapoport Nat Med, 2015) | Complete |
| | Combination study, no auto SCT; 2 cohorts | In planning |
| Ovarian | 10 patients | Enrolling |
| Melanoma | 6 patients | Enrolling; potential for combination study |
| Non-small cell lung cancer | 10 patients, Stage IIIb / IV NSCLC | Initiated Q4 2015 |
| Investigator Initiated studies | NCI: synovial sarcoma (16 patients) and melanoma (13 patients) | Complete |
| | ATTACK: Esophageal: 12 patients | Active; recruitment to resume |

*Pending analysis of cohort 3

Adaptimmune
TRANSFORMING T CELL THERAPY

# NY-ESO EXPRESSION ACROSS TUMOR TYPES

## NY-ESO-1 IS EXPRESSED AT LOW TO MEDIUM LEVELS ACROSS A WIDE RANGE OF TUMORS




Estimated Annual Deaths*

| | Melanoma | Ovarian | NSCLC | Myeloma |
|---|---|---|---|---|
| US[1] | 9,940 | 14,180 | 158,040 | 11,240 |
| EU[2] | 12,051 | 42,716 | 254,532 | 12,213 |

* HLA02 represents approx. 40-50% of these patients

Adaptimmune
TRANSFORMING T CELL THERAPY

1. Source: seer.cancer.gov
2. Source: eco.iarc.fr/eucan

## NY-ESO PROGRAM

### 2016 DEVELOPMENT MILESTONES AND DATA FLOW

| COMPLETED | TARGET DATE | MILESTONE |
|---|---|---|
| √ | 1H 2016 | Breakthrough designation for NY-ESO in synovial sarcoma |
| √ | 2H 2016 | Orphan drug designation for NY-ESO in soft tissue sarcoma |
| | 4Q 2016 | Additional phase I/II data from clinical studies in:<br>•Sarcoma •Myeloma •Lung •Ovarian •Melanoma |
| | 2H 2016 | Initiation of first combination study |
| | 2H 2016 | Initiation of Myxoid Round Cell Liposarcoma Study |
| | 4Q16/1Q17 | Initiation of pivotal synovial sarcoma study |

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

## ACCELERATING ADAPTIMMUNE'S WHOLLY-OWNED CLINICAL PIPELINE
APRIL 22, 2016

Adaptimmune

TRANSFORMING T CELL THERAPY



# NY-ESO CLINICAL PROGRAM UPDATE

## DEEP PIPELINE OF WHOLLY-OWNED TCRs

| INDICATION | RESEARCH | PRE-IND | PHASE I/II | STATUS |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | MAGE-A10 TCR dose escalation | | | Initiated Q4 2015 |
| Urothelial<br>Melanoma<br>Head and neck | MAGE-A10 TCR | | | Initiate in 2016 |
| Hepatocellular cancer | AFP TCR | | | IND open; enrollment in 2016 |
| Multiple cancer types | MAGE-A4 TCR | | | RAC and IND submission in 2017 |
| Multiple cancer types | Generation 2 and 3 TCRs | | | INDs in 2017+ |
| Multiple cancer types | Undisclosed | | | INDs from 2017+ |

Adaptimmune
TRANSFORMING T CELL THERAPY

## CANCER TESTIS EXPRESSION

### BROAD COVERAGE OF MANY CANCERS WITH ADAPTIMMUNE'S EXISTING TCR PIPELINE

| Indication | Frequency (%) | |
|---|---|---|
| | NY-ESO-1 | MAGE-A10 |
| Lung Squamous Cell | 26 | 33 |
| Bladder Cancer | 26 | 31 |
| Cutaneous Melanoma | 32 | 29 |
| Head and Neck | 11 | 14 |
| Ovarian Cancer | 13 | 12 |
| TN breast cancer | 19 | 10 |
| Endometrial Cancer | 7 | 7 |
| Esophageal Cancer | 11 | 18 |
| Gastric and Esophageal Cancer | 11 | 17 |
| Lung Adenocarcinoma | 12 | 10 |
| Cervical Cancer | 4 | 7 |
| Breast Cancer (all) | 5 | 3 |

Source: TGCA RNAseq datasets

≥30%
20-30%
≥ 45%

Adaptimmune
TRANSFORMING T CELL THERAPY

## CANCER TESTIS EXPRESSION

### BROAD COVERAGE OF MANY CANCERS WITH ADAPTIMMUNE'S EXISTING TCR PIPELINE

| Indication | Frequency (%) | | |
|---|---|---|---|
| | NY-ESO-1 | MAGE-A10 | MAGE-A4 |
| Lung Squamous Cell | 26 | 33 | 64 |
| Bladder Cancer | 26 | 31 | 38 |
| Cutaneous Melanoma | 32 | 29 | 23 |
| Head and Neck | 11 | 14 | 44 |
| Ovarian Cancer | 13 | 12 | 38 |
| TN breast cancer | 19 | 10 | 26 |
| Endometrial Cancer | 7 | 7 | 17 |
| Esophageal Cancer | 11 | 18 | 36 |
| Gastric and Esophageal Cancer | 11 | 17 | 32 |
| Lung Adenocarcinoma | 12 | 10 | 12 |
| Cervical Cancer | 4 | 7 | 23 |
| Breast Cancer (all) | 5 | 3 | 7 |

Source: TGCA RNAseq datasets

≥30%
20-30%
≥ 45%

Adaptimmune
TRANSFORMING T CELL THERAPY

## CANCER TESTIS EXPRESSION

### BROAD COVERAGE OF MANY CANCERS WITH ADAPTIMMUNE'S EXISTING TCR PIPELINE

| Indication | Frequency (%) | | | |
|---|---|---|---|---|
| | NY-ESO-1 | MAGE-A10 | MAGE-A4 | Expression by 1 or more |
| Lung Squamous Cell | 26 | 33 | 64 | 69 |
| Bladder Cancer | 26 | 31 | 38 | 50 |
| Cutaneous Melanoma | 32 | 29 | 23 | 48 |
| Head and Neck | 11 | 14 | 44 | 46 |
| Ovarian Cancer | 13 | 12 | 38 | 44 |
| TN breast cancer | 19 | 10 | 26 | 35 |
| Endometrial Cancer | 7 | 7 | 17 | 21 |
| Esophageal Cancer | 11 | 18 | 36 | 40 |
| Gastric and Esophageal Cancer | 11 | 17 | 32 | 35 |
| Lung Adenocarcinoma | 12 | 10 | 12 | 19 |
| Cervical Cancer | 4 | 7 | 23 | 26 |
| Breast Cancer (all) | 5 | 3 | 7 | 11 |

Source: TGCA RNAseq datasets

≥30%
20-30%
≥ 45%

Adaptimmune
TRANSFORMING T CELL THERAPY

## WHOLLY-OWNED PIPELINE

### 2016 DEVELOPMENT MILESTONES AND DATA FLOW

| COMPLETED | TARGET DATE | MILESTONE |
|---|---|---|
| √ | 1H 2016 | File and open IND for AFP TCR |
| | 2H 2016 | Complete enrollment in NSCLC dose-escalation study for MAGE-A10 |
| | 2H 2016 | Initiate AFP clinical study |
| | 2H 2016 | Initiate MAGE-A10 multi-tumor study |
| | 2017 | File IND for MAGE-A4 |

Adaptimmune
TRANSFORMING T CELL THERAPY

## SUMMARY

- Rapid progress with NY-ESO-1 in sarcoma, anticipate initiating pivotal trials around year end 2016
- Multiple studies examining efficacy of NY-ESO-1 in additional indications
- Expect to initiate combination trials with NY-ESO-1 and check-point inhibitor in 2016
- Broad tumor coverage across Adaptimmune's clinical pipeline
- Delivering on internal pipeline; 2 active INDs in the past 8 months
  - MAGE-A10 study in bladder cancer, head and neck cancer and melanoma, in addition to the ongoing NSCLC study
  - Open IND with AFP TCR; enrollment to start in 2016
- Next IND in 2017: MAGE-A4
  - High level of expression in multiple tumor types

Adaptimmune
TRANSFORMING T CELL THERAPY

ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

# ADAPTIMMUNE PIPELINE ENGINE: AN ABUNDANCE OF POTENTIAL TARGETS AND PRECLINICAL CANDIDATES

APRIL 22, 2016

Gwen Binder-Scholl, Ph.D.
Chief Technology Officer

Adaptimmune

TRANSFORMING T CELL THERAPY



# TCR IDENTIFICATION AND TESTING – THE PIPELINE ENGINE




- SPEAR T cell platform supports development across different HLA types
- 3 HLA types cover ~70% of the world population*

Adaptimmune
TRANSFORMING T CELL THERAPY

* www.allelefrequencies.net; internal model

# TCR IDENTIFICATION AND TESTING – THE PIPELINE ENGINE




Adaptimmune
TRANSFORMING T CELL THERAPY

# TECHNOLOGY ALLOWS ADAPTIMMUNE TO FIND TUMOR-ASSOCIATED TARGETS

## NEW TARGET SELECTION DRIVEN BY CLINICAL PRIORITIES

Multiple new targets identified across indications*




* Examples to demonstrate the breadth of targets; actual indications selected for development are not disclosed

Adaptimmune
TRANSFORMING T CELL THERAPY

## WHOLLY OWNED TARGET PIPELINE (APRIL 2016)

| Cancer indication | Top 3 Targets Identified for Each Indication (%) TCGA | | |
|---|---|---|---|
| | Target 1 | Target 2 | Target 3 |
| Sarcoma | (30%) | (21%) | |
| Endometrial | | (23%) | |
| Esophageal | (72%) | | (38%) |
| Lymphoid neoplasm | (29%) | (25%) | (25%) |
| Gastric | (51%) | | (45%) |
| Uveal melanoma | (100%) | (100%) | (100%) |
| Prostate | | | |
| Pancreatic | | | |
| Ovarian | | | |
| Lung AD | | (34%) | (34%) |
| Lung SqCC | | (47%) | |
| Liver HCC | | (36%) | (34%) |
| Head and Neck SCC | | (40%) | (38%) |
| Skin Cutaneous Melanoma | (88%) | (87%) | |
| Colon | | | |
| Breast | | | |
| Bladder | | | (40%) |
| AML | | | |

**Key:**

Target – New targets due assessment (peptides identified)

Adaptimmune
TRANSFORMING T CELL THERAPY

## WHOLLY OWNED TARGET PIPELINE (APRIL 2016)

| Cancer indication | Top 3 Targets Identified for Each Indication (%) TCGA | | |
|---|---|---|---|
| | Target 1 | Target 2 | Target 3 |
| Sarcoma | (30%) | (21%) | (17%) |
| Endometrial | (27%) | (23%) | |
| Esophageal | (72%) | | (38%) |
| Lymphoid neoplasm | (29%) | (25%) | (25%) |
| Gastric | (51%) | | (45%) |
| Uveal melanoma | (100%) | (100%) | (100%) |
| Prostate | (100%) | | (90-95%) |
| Pancreatic | (54%) | | (37%) |
| Ovarian | (54%) | | |
| Lung AD | | (34%) | (34%) |
| Lung SqCC | | (47%) | (46%) |
| Liver HCC | | (36%) | (34%) |
| Head and Neck SCC | | (40%) | (38%) |
| Skin Cutaneous Melanoma | (88%) | (87%) | |
| Colon | (55%) | (32%) | |
| Breast | (63%) | (41%) | (25%) |
| Bladder | | | (40%) |
| AML | (73%) | (50%) | |

**Key:**

Target – New targets due assessment (peptides identified)

Target – Targets in assessment

Adaptimmune
TRANSFORMING T CELL THERAPY

## WHOLLY OWNED TARGET PIPELINE (APRIL 2016)

| Cancer indication | Top 3 Targets Identified for Each Indication (%) TCGA | | |
|---|---|---|---|
| | Target 1 | Target 2 | Target 3 |
| Sarcoma | (30%) | (21%) | (17%) |
| Endometrial | (27%) | (23%) | |
| Esophageal | (72%) | (40%) | (38%) |
| Lymphoid neoplasm | (29%) | (25%) | (25%) |
| Gastric | (51%) | (48%) | (45%) |
| Uveal melanoma | (100%) | (100%) | (100%) |
| Prostate | (100%) | (99%) | (90-95%) |
| Pancreatic | (54%) | (49%) | (37%) |
| Ovarian | (54%) | | |
| Lung AD | (43%) | (34%) | (34%) |
| Lung SqCC | (58%) | (47%) | (46%) |
| Liver HCC | (44%) | (36%) | (34%) |
| Head and Neck SCC | (44%) | (40%) | (38%) |
| Skin Cutaneous Melanoma | (88%) | (87%) | |
| Colon | (55%) | (32%) | |
| Breast | (63%) | (41%) | (25%) |
| Bladder | (50%) | (41%) | (40%) |
| AML | (73%) | (50%) | |

Adaptimmune
TRANSFORMING T CELL THERAPY

**Key:**

Target – New targets due assessment (peptides identified)

Target – Targets in assessment

Target – Targets with TCRs in the discovery/optimisation programme

## WHOLLY OWNED TARGET PIPELINE (APRIL 2016)

| Cancer indication | Top 3 Targets Identified for Each Indication (%) TCGA | | |
|---|---|---|---|
| | Target 1 | Target 2 | Target 3 |
| Sarcoma | (30%) | (21%) | (17%) |
| Endometrial | (27%) | (23%) | |
| Esophageal | (72%) | (40%) | (38%) |
| Lymphoid neoplasm | (29%) | (25%) | (25%) |
| Gastric | (51%) | (48%) | (45%) |
| Uveal melanoma | (100%) | (100%) | (100%) |
| Prostate | (100%) | (99%) | (90-95%) |
| Pancreatic | (54%) | (49%) | (37%) |
| Ovarian | (54%) | | |
| Lung AD | (43%) | (34%) | (34%) |
| Lung SqCC | (58%) | (47%) | (46%) |
| Liver HCC | (44%) | (36%) | (34%) |
| Head and Neck SCC | (44%) | (40%) | (38%) |
| Skin Cutaneous Melanoma | (88%) | (87%) | |
| Colon | (55%) | (32%) | |
| Breast | (63%) | (41%) | (25%) |
| Bladder | (50%) | (41%) | (40%) |
| AML | (73%) | (50%) | |

Adaptimmune
TRANSFORMING T CELL THERAPY

**Key:**

Target – New targets due assessment (peptides identified)

Target – Targets in assessment

Target – Targets with TCRs in the discovery/optimisation programme

Blue – Cancer Testis Antigens

# MULTIPLE TARGETS TO ENTER CLINIC IN NEXT 3 YEARS

## MULTIPLE INDs FROM 2017 ONWARDS (TARGETS AND NEXT GENERATION)




- All programs are run under Adaptimmune-owned INDs.
- Next generation programs not represented on this chart.

Adaptimmune
TRANSFORMING T CELL THERAPY

# MULTIPLE TARGETS TO ENTER CLINIC IN NEXT 3 YEARS

## MULTIPLE INDs FROM 2017 ONWARDS (TARGETS AND NEXT GENERATION)




- All programs are run under Adaptimmune-owned INDs.
- Next generation programs not represented on this chart.

Adaptimmune
TRANSFORMING T CELL THERAPY

# MULTIPLE TARGETS TO ENTER CLINIC IN NEXT 3 YEARS

## MULTIPLE INDs FROM 2017 ONWARDS (TARGETS AND NEXT GENERATION)




- All programs are run under Adaptimmune-owned INDs.
- Next generation programs not represented on this chart.

Adaptimmune
TRANSFORMING T CELL THERAPY

* Early targets – attrition expected

# TCR IDENTIFICATION AND TESTING – THE PIPELINE ENGINE




Adaptimmune
TRANSFORMING T CELL THERAPY

# CANCER ANTIGEN SPECIFIC TCRs FROM CLONES AND LIBRARIES

## ORIGINAL ISOLATES DISPLAY A WIDE RANGE OF AFFINITIES




MAGE-A4

Selected from a pool of 69 parental TCRs

MAGE-A10

Selected from a pool of 21 parental TCRs *supra-natural TCR*

AFP

Single clone

Adaptimmune
TRANSFORMING T CELL THERAPY

*Aleksic, M. et al. (2012). Eur J Immunol 10.1002/eji.201242606*

# AFFINITY OPTIMIZATION IS IMPORTANT IN ALL CASES SO FAR

## INDEPENDENT OF STARTING AFFINITY, OPTIMIZATION IS RELEVANT




- Having multiple parental TCRs to start from allows selection of the most specific TCR.
- The ideal affinity is different for each TCR and not possible to predict.

Adaptimmune
TRANSFORMING T CELL THERAPY

*Aleksic, M. et al. (2012). Eur J Immunol 10.1002/eji.201242606*

## EACH TCR HAS A WINDOW OF ENHANCED POTENCY

IT IS POSSIBLE TO OVER-ENGINEER – THIS IS CAREFULLY MONITORED




Adaptimmune
TRANSFORMING T CELL THERAPY

# TCR IDENTIFICATION AND TESTING – THE PIPELINE ENGINE




- TCR specificity is mapped by X-scanning
- Alloreactivity and further TCR specificity tested in cell-based assays
- Potency tested in primary tumor and tumor cell lines

Adaptimmune
TRANSFORMING T CELL THERAPY

## SUMMARY

### ADAPTIMMUNE HAS A PIPELINE FOR AN INDUSTRY

- Multiple tumor associated targets across oncology indications – nearly every indication can be addressed
- Affinity optimization is important for optimal efficacy, but…
  - The ideal affinity must be empirically determined
  - Adaptimmune has a unique set of tools to ensure specificity of engineered TCRs
- The SPEAR T cell platform supports development across multiple HLA types
- Multiple company-owned INDs from 2017 onwards
  - Includes new targets, and next generation cells

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE SCIENTIFIC ADVISORY BOARD

**Crystal Mackall, M.D., *Chair, Adaptimmune Scientific Advisory Board***; Professor of Pediatrics and Medicine; Associate Director of the Stanford Cancer Institute

**Nabil Ahmed, M.D.**, Associate Professor, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center; Center for Cell and Gene Therapy, Houston Methodist Hospital, Baylor College of Medicine

**Thomas Gajewski, M.D., Ph.D.**, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine - Section of Hematology/Oncology, University of Chicago Medical Center

**Michael Dustin, Ph.D.**, Professor of Immunology and Wellcome Principal Research Fellow, Director of Research of the Kennedy Institute, Oxford, UK

**Steve Grupp, M.D., Ph.D.**, Novotny Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Director, Cancer Immunotherapy Frontier Program; Director of Translational Research, Children's Hospital of Philadelphia

**Keith Flaherty, M.D.**, Keith Flaherty, M.D., Professor, Medicine, Harvard Medical School; Director of Termeer Center for Target Therapy, Cancer Center, Massachusetts General Hospital

**Arlene Sharpe, M.D., Ph.D.**, Fabyan Professor of Comparative Pathology, Microbiology and Immunobiology, Harvard Medical School Vice Chair for Education, Pathology, Harvard Medical School; Co-Director, The Harvard Institute of Translational Immunology (HITI)

**Wolf Fridman, M.D.**, Ph.D., Professor Emeritus of Immunology , Paris Descartes University Medical School, Paris, France; President, Canceropole Ile de France

**Mario Sznol, M.D.**, Professor, Internal Medicine; Leader, Disease-Related Research Team, Melanoma and Renal cell Carcinoma; Vice-Chief, Medical Oncology; Co-Director, Yale Skin SPORE, Yale Cancer Center

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

## MANUFACTURING EXCELLENCE AND COMMERCIAL DELIVERY
APRIL 22, 2016

Adaptimmune

TRANSFORMING T CELL THERAPY



# MANUFACTURING PROCESS OVERVIEW

**Patient Screening**
(HLA-A201 and NY-ESO-1 Antigen)



Clinical sites across the globe
Fully closed system
8-10 day release testing

Adaptimmune
TRANSFORMING T CELL THERAPY

# MANUFACTURING PROCESS OVERVIEW




Clinical sites across the globe
Fully closed system
8-10 day release testing

Adaptimmune
TRANSFORMING T CELL THERAPY

# MANUFACTURING PROCESS OVERVIEW




- Clinical sites across the globe
- Fully closed system
- 8-10 day release testing

Adaptimmune
TRANSFORMING T CELL THERAPY

# MANUFACTURING PROCESS OVERVIEW




Adaptimmune
TRANSFORMING T CELL THERAPY

# MANUFACTURING PROCESS OVERVIEW




Adaptimmune
TRANSFORMING T CELL THERAPY

# CONTINUUM OF MANUFACTURING PROCESS DEVELOPMENT

## INITIALLY DEVELOPED AT UNIVERSITY OF PENNSYLVANIA*

| | | Academic process |
|---|---|---|
| *Cell* | Commercial expansion method | √ |
| | Fully closed system | |
| | Industry standard Good Manufacturing Practices | |
| | Contract manufacturer – fully controlled and owned process | |
| | Freeze both ends | |
| | Wholly owned facility | |
| | Automation of some process steps | |
| | Automation of most / all process steps | |
| *Vector* | Academic vector backbone | √ |
| | Academic vector production – fixed scale | √ |
| | Proprietary vector backbone | |
| | Proprietary vector production - fixed scale | |
| | Fully scalable vector production | |
| | | ***2006*** |

Adaptimmune
TRANSFORMING T CELL THERAPY

*Levine et al, J Immunol, 1997

## CONTINUUM OF MANUFACTURING PROCESS DEVELOPMENT

### BROUGHT IN HOUSE IN 2013 – MINIMAL CHANGES WITH GREATER CONTROL

| | | Academic process | Adaptimmune process |
|---|---|---|---|
| *Cell* | Commercial expansion method | √ | √ |
| | Fully closed system | | √ |
| | Industry standard Good Manufacturing Practices | | √ |
| | Contract manufacturer – fully controlled and owned process | | √ |
| | Freeze both ends | | |
| | Wholly owned facility | | |
| | Automation of some process steps | | |
| | Automation of most / all process steps | | |
| *Vector* | Academic vector backbone | √ | √ |
| | Academic vector production – fixed scale | √ | √ |
| | Proprietary vector backbone | | |
| | Proprietary vector production - fixed scale | | |
| | Fully scalable vector production | | |
| | | ***2006*** | ***2013*** |

Adaptimmune
TRANSFORMING T CELL THERAPY

# CONTINUUM OF MANUFACTURING PROCESS DEVELOPMENT

## OPTIMIZED FOR COMMERCIAL USE AND OPENING A COMMERCIAL FACILITY

| | | Academic process | Adaptimmune process | Commercial ready process |
|---|---|---|---|---|
| *Cell* | Commercial expansion method | √ | √ | √ |
| | Fully closed system | | √ | √ |
| | Industry standard Good Manufacturing Practices | | √ | √ |
| | Contract manufacturer – fully controlled and owned process | | √ | √ |
| | Freeze both ends | | | √ |
| | Wholly owned facility | | | √ |
| | Automation of some process steps | | | √ |
| | Automation of most / all process steps | | | |
| *Vector* | Academic vector backbone | √ | √ | |
| | Academic vector production – fixed scale | √ | √ | |
| | Proprietary vector backbone | | | √ |
| | Proprietary vector production - fixed scale | | | √ |
| | Fully scalable vector production | | | |
| | | ***2006*** | ***2013*** | ***2016 - 2017*** |

Adaptimmune
TRANSFORMING T CELL THERAPY

# CONTINUUM OF MANUFACTURING PROCESS DEVELOPMENT

## NEXT GENERATION IMPROVEMENTS UNDERWAY

| | | Academic process | Adaptimmune process | Commercial ready process | Next generation process |
|---|---|---|---|---|---|
| *Cell* | Commercial expansion method | √ | √ | √ | √ |
| | Fully closed system | | √ | √ | √ |
| | Industry standard Good Manufacturing Practices | | √ | √ | √ |
| | Contract manufacturer – fully controlled and owned process | | √ | √ | √ |
| | Freeze both ends | | | √ | √ |
| | Wholly owned facility | | | √ | √ |
| | Automation of some process steps | | | √ | √ |
| | Automation of most / all process steps | | | | √ |
| *Vector* | Academic vector backbone | √ | √ | | |
| | Academic vector production – fixed scale | √ | √ | | |
| | Proprietary vector backbone | | | √ | √ |
| | Proprietary vector production - fixed scale | | | √ | |
| | Fully scalable vector production | | | | √ |
| | | ***2006*** | ***2013*** | ***2016 - 2017*** | ***2018*** |

Adaptimmune
TRANSFORMING T CELL THERAPY

## KEY OBJECTIVES OF *EX VIVO* T CELL MANUFACTURING

- Select the right T cells for anti-tumor efficacy
- Gene modify and activate / rejuvenate these T cells to generate potency
- Expand these T cells to meet the target dose for patients
- Build in manufacturing flexibility – freeze the product at both ends

Adaptimmune's manufacturing meets these objectives

Adaptimmune
TRANSFORMING T CELL THERAPY

## ABILITY TO EXPAND THE T CELLS TO DELIVER REQUIRED DOSE

### T CELLS EXPANDED ON AVERAGE 40-FOLD IN EX VIVO CULTURE




- Minimizes vector usage at culture start (cost of goods reduction)
- Apheresis always yields sufficient cells for manufacture
- Target patient dose routinely achieved

Adaptimmune
TRANSFORMING T CELL THERAPY

## ABILITY TO EXPAND THE T CELLS TO DELIVER REQUIRED DOSE

### ROUTINELY MEETS REQUIRED PATIENT DOSE




Adaptimmune
TRANSFORMING T CELL THERAPY

** dependent on frequency of gene transduction – typically ~50%*

## ABILITY TO EXPAND THE T CELLS TO DELIVER REQUIRED DOSE

CULTURE BEYOND 6 DAYS REQUIRED TO ACHIEVE ADEQUATE PRODUCT




*The majority of expansion occurs day 6-12*

Adaptimmune
TRANSFORMING T CELL THERAPY

## ABILITY TO EXPAND THE T CELLS TO DELIVER REQUIRED DOSE

### RELEASE TESTING – AN IMPORTANT SAFETY REQUIREMENT




\+ *Release testing (10 day)* = 20-22 days vein to vein

All engineered T cell therapy products are required to undergo post production release testing

Adaptimmune
TRANSFORMING T CELL THERAPY

## THE METHOD OF T CELL MANUFACTURING IS IMPORTANT

### NOT ALL METHODS ARE EQUAL

- T cells are expanded through triggering of the TCR and provision of a second signal (to overcome peripheral tolerance mechanisms)
- Original manufacturing method – used in academic studies
  - Anti-CD3 (TCR signal) antibody (OKT-3) with IL-2*
  - Exogenous feeder cells often added to improve expansion (co-stimulation)**

Adaptimmune
TRANSFORMING T CELL THERAPY

* Better et al, 2014 ASCO abstract #3079 (Kite)
** Morgan et al, Science, 2006; Riddell and Greenberg, J Immunol Meth (1990)

## MANUFACTURING THE BEST T CELLS

### METHODS OF MANUFACTURING



Dynabeads® CD3/CD28 reagent**

- Commercial method:
  - Co-ordinated activation and co-stimulation through CD3 and CD28 ligation*
  - Magnetic beads bound to anti-CD3 and CD28 antibodies - easy to add and remove
  - Good safety record to date – hundreds of patients treated**
  - Used by Novartis under exclusive license for CAR-T***

Adaptimmune
TRANSFORMING T CELL THERAPY

* Levine et al, J Immunol, 1997
** source: internal
*** source: Thermo Fisher website

## MANUFACTURING THE BEST T CELLS

### METHODS OF MANUFACTURING



Dynabeads® CD3/CD28 reagent**

- Commercial method:
  - Co-ordinated activation and co-stimulation through CD3 and CD28 ligation*
  - Magnetic beads bound to anti-CD3 and CD28 antibodies - easy to add and remove
  - Good safety record to date – hundreds of patients treated**
  - Used by Novartis under exclusive license for CAR-T***
  - Patented IP exclusively licensed to Adaptimmune for TCR engineered T cell therapy
  - De-risks regulatory path to licensure - all of our clinical data has been generated using this process
  - Supports positive selection for CD4 and CD8 T cells

Adaptimmune
TRANSFORMING T CELL THERAPY

* Levine et al, J Immunol, 1997
** source: internal
*** source: Thermo Fisher website

## MANUFACTURING THE BEST T CELLS

### THE IMPORTANCE OF T CELL ACTIVATION WITH CO-STIMULATION

Benefits of the CD3/28 method (compared to anti-CD3 with IL-2)

- Have a higher telomerase activity
- Are younger (cells express the CD27+ and CD28+ markers)
- Have longer telomeres and greater replicative potential
- Have more of a central memory profile
- Have lower levels of senescence

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Better et al, 2014 ASCO abstract #3079 (Kite); Weng et al, JExpMed (1996)); Hamann et al, J Exp Med (1997); and Azuma, Phillips and Lanier, J Immunol (1993); Barrett et al, Cytotherapy (2014)

## MANUFACTURING THE BEST T CELLS

### THE BENEFITS OF SIMULTANEOUS STIMULATION AND CO-STIMULATION

| | CD45RO+/CD62L+ | CD27+/CD28+ | |
|---|---|---|---|
| OKT3+IL-2* | 30% +/- 2 | 31% +/- 1 | |
| CD3/CD28 | 76% +/- 4 * | 81% +/- 6 * | Adaptimmune process |
| | Markers of central memory | Markers of T cell youth | |

Adaptimmune process (CD3/CD28 beads) significantly increases telomere length vs OKT3+IL-2




Adaptimmune
TRANSFORMING T CELL THERAPY

Data from: Barrett et al, Cytotherapy 2014
*method reported in Better et al, 2014 ASCO abstract #3079

## MANUFACTURING THE BEST T CELLS

### CD3/CD28 BEAD METHOD PRODUCES LONG TERM PERSISTING T CELLS

CAR and TCR products associated with long term persistence use this technology; some examples…




*Scholler*




*Tebas*




*Rapoport*
*(Adaptimmune data)*

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Scholler et al, Mol Ther (2013); Tebas et al, Blood (2013); Rapoport et al, Nat Med (2015); Porter et al, STM (2015)

# MANUFACTURING THE BEST T CELLS

## CDC3/CD28 METHOD PRODUCES LONG TERM PERSISTING T CELLS




- Long term expression of the TCR – no gene silencing
- Programming of central memory and stem central memory cells which are associated with enhanced antitumor responses

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Gattinoni et al, Nat Med, 2011

## MANUFACTURED T CELLS ARE HIGHLY POTENT

### ANTIGEN-SPECIFIC KILLING IN A THREE DIMENSIONAL TUMOR MODEL




Adaptimmune
TRANSFORMING T CELL THERAPY

*GFP positive tumor – tumor size is measured by taking the average GFP fluorescence in the whole well; addition of T cells increases tumor size because they infiltrate the tumor

## MEETING CLINICAL SUPPLY

### EXPERIENCED, INDUSTRY-LEADING CONTRACT MANUFACTURERS

PCT (Allendale, NJ)

- >20,000 products made treating >6,000 patients
- 16 years of operation
- US and EU supply possible
- Dedicated space allocated for Adaptimmune

MaSTherCell (Gosselies, BE)

- Authorized by AFMPS in 2013
- Acquired by Orgenesis in 2015
- EU supply

PCT

MaSTherCell

Working with professional non-academic CMOs; well-controlled processes, GMP trained staff, commercial quality systems

Adaptimmune
TRANSFORMING T CELL THERAPY

Source: www.pctcaladrius.com; www.masthercell.com

## MEETING COMMERCIAL SUPPLY

### DEDICATED MANUFACTURING PLANT – OPENING EARLY 2017


- Located in the Philadelphia Navy Yard Biotechnology Park
- 10 minutes from the Philadelphia Airport; ideal for product logistics

Adaptimmune
TRANSFORMING T CELL THERAPY

## MEETING COMMERCIAL SUPPLY

### DEDICATED MANUFACTURING PLANT

SECOND FLOOR cGMP SUITE

- Potential for up to 1,200 patients per year
- Build in a module fashion (3 planned, one shown here)
- Option to bring vector manufacture in-house

Adaptimmune
TRANSFORMING T CELL THERAPY

## PROCESS OVERVIEW

### KEY PROCESS ELEMENTS TO SUPPORT COMMERCIAL DELIVERY

Freeze at both ends enables flexible manufacturing scheduling




Adaptimmune
TRANSFORMING T CELL THERAPY

## PROCESS OVERVIEW

### KEY PROCESS ELEMENTS TO SUPPORT COMMERCIAL DELIVERY

Positive selection of T cells






Adaptimmune
TRANSFORMING T CELL THERAPY

# PROCESS OVERVIEW

## KEY PROCESS ELEMENTS TO SUPPORT COMMERCIAL DELIVERY







Adaptimmune
TRANSFORMING T CELL THERAPY

## PROCESS OVERVIEW

### KEY PROCESS ELEMENTS TO SUPPORT COMMERCIAL DELIVERY




FULLY CLOSED CELL MANUFACTURING PROCESS

Adaptimmune
TRANSFORMING T CELL THERAPY

# INCORPORATING AUTOMATION IN THE CELL PROCESS

## REDUCES COST AND PROMOTES CONSISTENCY




- Automate most complex steps
- Retain flexibility in any automation plan, as the process will evolve with emerging scientific findings

Adaptimmune
TRANSFORMING T CELL THERAPY

## OPTIMIZING TRANSFER OF TCR TO THE CELLS

### LENTIVIRAL VECTOR EFFICIENTLY DELIVERS TCR TO T CELLS

- Well established safety profile in T cells – no cases of insertional oncogenesis
- Efficient transduction at low vector input per cell (multiplicity of infection of 1 unit per cell)
- Optimized backbone for safety – WPRE removed to reduce perceived safety risks




Adaptimmune
TRANSFORMING T CELL THERAPY

Source: Kingsman, Mitrophanous, Olsen, Gene Therapy 2005

## MEETING LENTIVIRAL VECTOR COMMERCIAL SUPPLY

### CURRENT PROCESS IS COMMERCIAL READY; OPTIMIZATION ONGOING

- Development of proprietary process for initial commercial supply
  - Optimized backbones for transfer vector and packaging plasmids
  - Developed upstream and downstream production methods




- Dedicated process development group to maximize production yield
  - Adapt this process to scalable bioreactors
  - Establish a packaging cell line to enable continuous production in bioreactors

Adaptimmune
TRANSFORMING T CELL THERAPY

# BRINGING IT ALL TOGETHER FOR COMMERCIAL DELIVERY

| | | 2006 Academic process | 2013 Adaptimmune process | 2016 Commercial ready process |
|---|---|---|---|---|
| *Cell* | Commercial expansion method | √ | √ | √ |
| | Fully closed system | | √ | √ |
| | Industry standard Good Manufacturing Practices | | √ | √ |
| | Contract manufacturer – fully controlled and owned process | | √ | √ |
| | Freeze both ends | | | √ |
| | Wholly owned facility | | | √ |
| | Automation of some process steps | | | √ |
| | Automation of most / all process steps | | | |
| *Vector* | Academic vector backbone | √ | √ | |
| | Academic vector production – fixed scale | √ | √ | |
| | Proprietary vector backbone | | | √ |
| | Proprietary vector production - fixed scale | | | √ |
| | Fully scalable vector production | | | |

√

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE MANUFACTURING SUMMARY

NOT ALL T CELL MANUFACTURING METHODS ARE EQUAL

- Proprietary T cell expansion method
  - Produces young, potent, persistent cells
  - Routinely meets required patient doses
- Commercial ready process in place
  - Fully closed
  - No significant changes since initial trials – de-risks regulatory path
- Supply in place
  - US and EU contract manufacturers in place
  - Dedicated manufacturing plant opening in 2017

Adaptimmune
TRANSFORMING T CELL THERAPY

ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

# CONCLUSION

James Noble
Chief Executive Officer, Adaptimmune

Adaptimmune
TRANSFORMING T CELL THERAPY



## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

- Proprietary SPEAR T cell technology uniquely delivers:
  - Correctly identified targets
  - Specificity and optimal affinity
  - "Supra-natural" TCRs to accelerate programs
  - Enhanced effectiveness of TCRs: Generation 2 and 3
- No other company can currently deliver all of these

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

- Proprietary SPEAR T cell technology uniquely delivers:
  - Correctly identified targets
    - Mass spectrometry critical
  - Specificity and optimal affinity
    - Adaptimmune platform finds window of safety and cross reactivity for each TCR
  - "Supra-natural" TCRs to accelerate programs
    - Numerous parental TCRs derived from libraries lead to multiple INDs
  - Enhanced effectiveness of TCRs: Generation 2 and 3
    - Generation 2: Designed to overcome tumor microenvironment
    - Generation 3: Designed to induce epitope spreading and break tumor immune tolerance
- No other company can currently deliver all of these
  - New data on above presented today

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

**Most compelling clinical data in the field**

- Multiple clinical responses in synovial sarcoma, a solid tumor
- Over 90% response rate in multiple myeloma study in conjunction with ASCT
- No other company is as far advanced as Adaptimmune in the clinic with a TCR T cell

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

**Clear scientific leadership in the field of T cell engineering**

**Most compelling clinical data in the field**

- Multiple clinical responses in synovial sarcoma, a solid tumor
  - New images showing resolution of large solid lesions
  - Cohort 2 suggests responses in low expressers
  - Cohort 3 suggests importance of fludarabine
  - Cohort 4 starting shortly
- Over 90% response rate in multiple myeloma study in conjunction with ASCT
  - Median overall survival of ~3 years
- No other company is as far advanced as Adaptimmune in the clinic with a TCR T cell
  - New updates presented on both diseases today
  - Pivotal studies to start in 4Q16/1Q17

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

Clear scientific leadership in the field of T cell engineering

Most compelling clinical data in the field

Deep pipeline across major cancers

- Company INDs open for NY-ESO, MAGE-A10 and AFP
- These TCRs all derive from Adaptimmune's proprietary technology
- No other company has routinely delivered INDs from in-house TCR platform

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

Clear scientific leadership in the field of T cell engineering

Most compelling clinical data in the field

Deep pipeline across major cancers

- Company INDs open for NY-ESO, MAGE-A10 and AFP
  - MAGE-A4 next IND 2017
  - Generation 2 INDs from 2017
- These TCRs all derive from Adaptimmune's proprietary technology
  - Active programs give broad coverage of tumors
- No other company has routinely delivered INDs from in-house TCR platform

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Financial discipline and position to fund business

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

Clear scientific leadership in the field of T cell engineering

Most compelling clinical data in the field

Deep pipeline across major cancers

Financial discipline and position to fund business

- Total liquidity position of $248 million*
- Current capital can fund the business through mid-2018

Adaptimmune
TRANSFORMING T CELL THERAPY

*As of December 31, 2015

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Financial discipline and position to fund business
- Proven ability to execute

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

Clear scientific leadership in the field of T cell engineering

Most compelling clinical data in the field

Deep pipeline across major cancers

Financial discipline and position to fund business

Proven ability to execute (1)

- Milestones met through April 2016
  - Expanded into autoimmune
  - Expanded strategic immunotherapy collaboration with GSK
  - Secured NY-ESO breakthrough therapy designation in synovial sarcoma
  - Secured NY-ESO orphan drug designation
  - IND opened for AFP in hepatocellular cancer

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Financial discipline and position to fund business
- Proven ability to execute (2)

- Manufacturing processes optimized
  - Proprietary T cell expansion method
  - Commercial-ready process in place
  - EU and US contract manufacturers in place

Adaptimmune
TRANSFORMING T CELL THERAPY

## ADAPTIMMUNE: LEADING THE TCR T CELL SPACE

- Clear scientific leadership in the field of T cell engineering
- Most compelling clinical data in the field
- Deep pipeline across major cancers
- Financial discipline and position to fund business
- Proven ability to execute

**Goal: first TCR T cell therapy to market**

Adaptimmune
TRANSFORMING T CELL THERAPY

# ADAPTIMMUNE INVESTOR AND ANALYST DAY 2016

APRIL 22, 2016

Adaptimmune

TRANSFORMING T CELL THERAPY



**Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board**

PHILADELPHIA, Pa. and OXFORD, UK, April 22, 2016 — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB). Crystal Mackall, M.D., Professor of Pediatrics and Medicine and Associate Director of the Stanford Cancer Institute, will serve as Chair of the SAB.

The SAB will serve as a strategic resource for Adaptimmune and help to steer the company's development efforts in the field of immuno-oncology.

"Adaptimmune is the clear leader in the TCR T-cell therapy space, and I'm very pleased to join their scientific advisory board as Chair at this important time in their evolution," said Dr. Mackall.

"Our inaugural scientific advisory board members bring a wealth of experience in areas including gene therapy, immunotherapy and oncology, and we are honored to have such a prestigious group of advisors," said James Noble, Adaptimmune's Chief Executive Officer. "Their insights and guidance will be invaluable as we continue to move our pipeline of affinity optimized T-cell therapies forward."

The inaugural members of Adaptimmune's scientific advisory board are:

- **Crystal Mackall, M.D., Chair, Adaptimmune Scientific Advisory Board**; Professor of Pediatrics and Medicine; Associate Director of the Stanford Cancer Institute
- **Nabil Ahmed, M.D.**, Associate Professor, Department of Pediatrics, Texas Children's Hospital, Texas Children's Cancer Center; Center for Cell and Gene Therapy, Houston Methodist Hospital, Baylor College of Medicine
- **Michael Dustin, Ph.D.**, Professor of Immunology and Wellcome Principal Research Fellow, Director of Research of the Kennedy Institute
- **Keith Flaherty, M.D.**, Professor, Medicine, Harvard Medical School; Director of Termeer Center for Target Therapy, Cancer Center, Massachusetts General Hospital
- **Wolf Fridman, M.D., Ph.D.,** Professor Emeritus of Immunology, Paris Descartes University Medical School, Paris, France; President, Canceropole Ile de France
- **Thomas Gajewski, M.D., Ph.D.**, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine - Section of Hematology/Oncology, University of Chicago Medical Center
- **Stephan Grupp, M.D., Ph.D.,** Novotny Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Director, Cancer Immunotherapy Frontier Program; Director of Translational Research, Children's Hospital of Philadelphia
- **Arlene Sharpe, M.D., Ph.D.**, Fabyan Professor of Comparative Pathology, Microbiology and Immunobiology, Harvard Medical School; Vice Chair for Education, Pathology, Harvard Medical School; Co-Director, Harvard Institute of Translation Immunology (HITI), Harvard Medical School

---

- **Mario Sznol, M.D.**, Professor, Internal Medicine; Leader, Disease-Related Research Team, Melanoma and Renal cell Carcinoma; Vice-Chief, Medical Oncology; Co-Director, Yale Skin SPORE, Yale Cancer Center

**About Adaptimmune**

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body's own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

**Forward-Looking Statements**

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts@adaptimmune.com

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

---

**Exhibit 99.3**


**Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology**

PHILADELPHIA, Pa. and OXFORD, UK, April 22, 2016 — Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity Receptor T-cells) to describe its proprietary technology.

The SPEAR T-cells brand is intended to symbolize the vital role that Adaptimmune's enhanced affinity T-cell receptors play in targeting cancer.

Adaptimmune has a history of scientific leadership in the field of T-cell engineering and the company's proprietary T-cell engineering platform, developed over the last 15 years, has generated a strong pipeline of T-cell therapies.

"Affinity optimized T-cell receptors are essential to the fight against cancer," said James Noble, Adaptimmune's Chief Executive Officer. "Our SPEAR T-cell technology is unique in delivering correctly identified targets and enhanced affinity TCRs that have the potency needed to attack tumors, but also the optimum specificity to minimize risks of cross-reactivity. Our proprietary technology provides us with 'supra-natural' TCRs that enable the acceleration of our programs and also facilitates our development of second generation TCRs."

**About Adaptimmune**

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body's own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

**Forward-Looking Statements**

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties

---

that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts@adaptimmune.com

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

---